Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
14 "Byoung-Gie Kim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Efficacy of Chemotherapy Following Prior PARP-Inhibitor Treatment in Patients with Ovarian Cancer
Jung Chul Kim, Junsik Park, Yong Jae Lee, Eun Ji Nam, Sang Wun Kim, Sung-Hoon Kim, Young Tae Kim, Se Ik Kim, Jae-Weon Kim, Byoung-Gie Kim, Jung-Yun Lee
Received December 23, 2024  Accepted March 16, 2025  Published online March 19, 2025  
DOI: https://doi.org/10.4143/crt.2024.1202    [Accepted]
AbstractAbstract PDF
Purpose
Considering the current lack of consensus on post-poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) treatment strategies, this study aimed to evaluate the efficacy of subsequent therapy and compare the outcomes of regimes in patients with recurrent ovarian cancer after PARPi treatment.
Materials and Methods
This multi-center retrospective cohort study analyzed data on patients diagnosed with ovarian cancer between January 2012 and June 2023 who had previously used PARPi after first- to fourth-line platinum-based chemotherapy. The primary endpoint was progression-free survival (PFS), which was the interval between recurrence after using PARPi and subsequent recurrence in the case of recurrence.
Results
Of 318 patients, 147/318 (46.2%) recurred after the PARPi maintenance. Patients were categorized into groups based on subsequent therapy except non-treated (11/147, 7.5%): platinum-based chemotherapy (89/147, 60.5%), non-platinum-based chemotherapy (21/147, 14.3%), other treatments (26/147, 17.7%), and the median PFS (mPFS) for each group were 7.3, 4.8 and 11.4 months, respectively. Among the platinum-based chemotherapy group, the gemcitabine + carboplatin regimen demonstrated a longer mPFS (10.1 months) than the other regimens (6.6 months, p=0.0194). In non-platinum-based chemotherapy, no statistically significant differences were observed among the regimens. And, in the other therapy group, where the proportion of patients with oligometastasis was as high as 88.5%, no significant differences were observed among the therapies, including other modalities.
Conclusion
In the subsequent chemotherapy of recurrent ovarian cancer after platinum-based chemotherapy and PARPi, the gemcitabine + carboplatin regimen demonstrated a potential to delay recurrence more effectively compared to other therapies.
  • 540 View
  • 67 Download
Close layer
Gynecologic cancer
Effect of Waiting Time from Pathological Diagnosis to Definitive Concurrent Chemoradiation for Cervical Cancer on Overall Survival
Kyoung Won Noh, Bomi Kim, Chel Hun Choi, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Duk-Soo Bae, Won Kyung Cho, Won Park, Yoo-Young Lee
Cancer Res Treat. 2022;54(1):245-252.   Published online April 15, 2021
DOI: https://doi.org/10.4143/crt.2021.023
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to evaluate the effect of waiting time, from diagnosis to initiation of definitive concurrent chemoradiation (CCRT), on overall survival in cervical cancer patients.
Materials and Methods
Patients with cervical cancer who were treated with definitive CCRT between 2000 and 2017 were retrospectively reviewed. Time from initial pathological diagnosis to definitive CCRT was analyzed both as a continuous variable (per day) and as a categorical variable in two groups (group 1 ≤ median, group 2 > median). Patients with a waiting time of more than 60 days were excluded.
Results
The median waiting time was 14 days (0-60). There were differences between group 1 and group 2 in age and chemotherapy regimens. However, no significant difference was found in the International Federation of Gynecology and Obstetrics stage, cell type, or the number of cycles of chemotherapy received during CCRT. A longer waiting time was associated with poorer overall survival on the Kaplan-Meier curve (group 1 vs. group 2, p=0.042). On multivariate analysis, intervals as either a continuous variable (hazard ratio [HR], 1.023; 95% confidence interval [CI], 1.006 to 1.040; p=0.007) or a categorical variable (HR, 1.513; 95% CI, 1.073 to 2.134; p=0.018), FIGO stage, cell type, and the number of cycles of chemotherapy received during CCRT were significant independent prognostic factors for overall survival.
Conclusion
A shorter waiting time from pathological diagnosis to definitive CCRT showed benefit on overall survival. Our findings suggest that an effort to minimize waiting times should be recommended in cervical cancer patients who are candidates for CCRT.

Citations

Citations to this article as recorded by  
  • Effect of waiting time for radiotherapy after last induction chemotherapy on prognosis of locally advanced nasopharyngeal carcinoma
    Kui‐Xuan Zhu, Ting Ding, Yi‐Min E, Hong‐Wei Yang, Rui‐Ping Wu, Run‐Jia Liu, Ling‐Li Zhou, Wen‐Jie Fu, Mei‐Ping Jiang, Xiao‐Li Wang
    Head & Neck.2024; 46(5): 1189.     CrossRef
  • An Innovative Thermal Imaging Prototype for Precise Breast Cancer Detection: Integrating Compression Techniques and Classification Methods
    Khaled S. Ahmed, Fayroz F. Sherif, Mohamed S. Abdallah, Young-Im Cho, Shereen M. ElMetwally
    Bioengineering.2024; 11(8): 764.     CrossRef
  • Prognostic impact of waiting time between diagnosis and treatment in patients with cervical cancer: A nationwide population-based study
    Amy P. Hack, Ronald P. Zweemer, Trudy N. Jonges, Femke van der Leij, Cornelis G. Gerestein, Max Peters, Ina M. Jürgenliemk-Schulz, Peter S.N. van Rossum
    Gynecologic Oncology.2022; 165(2): 339.     CrossRef
  • The Role of Conization before Radical Hysterectomy in Cervical Cancer including High Risk Factors of Recurrence: Propensity Score Matching
    Chi-Son Chang, Ji Song Min, Ki Hyeon Song, Chel Hun Choi, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Yoo-Young Lee
    Cancers.2022; 14(16): 3863.     CrossRef
  • Survival outcomes following treatment delays among patients with early-stage female cancers: a nationwide study
    Yu Min, Zheran Liu, Rendong Huang, Ruidan Li, Jing Jin, Zhigong Wei, Ling He, Yiyan Pei, Ning Li, Yongllin Su, Xiaolin Hu, Xingchen Peng
    Journal of Translational Medicine.2022;[Epub]     CrossRef
  • 7,169 View
  • 197 Download
  • 7 Web of Science
  • 5 Crossref
Close layer
Gynecologic Cancer
Early Metabolic Response Assessed Using 18F-FDG-PET/CT for Image-Guided Intracavitary Brachytherapy Can Better Predict Treatment Outcomes in Patients with Cervical Cancer
Nalee Kim, Won Park, Won Kyung Cho, Duk-Soo Bae, Byoung-Gie Kim, Jeong-Won Lee, Tae-Joong Kim, Chel Hun Choi, Yoo-Young Lee, Young Seok Cho
Cancer Res Treat. 2021;53(3):803-812.   Published online December 9, 2020
DOI: https://doi.org/10.4143/crt.2020.1251
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to identify the prognostic value of early metabolic response assessed using 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) during radiation therapy (RT) for cervical cancer.
Materials and Methods
We identified 116 patients treated with definitive RT, including FDG-PET/CT–guided intracavitary brachytherapy, between 2009 and 2018. We calculated parameters including maximum (SUVmax) and mean standardized uptake values (SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) for baseline FDG-PET/CT (PETbase) and image-guided brachytherapy planning FDG-PET/CT (PETIGBT). Multivariable analyses of disease-free survival (DFS) and overall survival (OS) were performed.
Results
We observed a time-dependent decrease in PET parameters between PETbase and PETIGBT; ΔSUVmax, ΔSUVmean, ΔMTV, and ΔTLG were 65%, 61%, 78%, and 93%, respectively. With a median follow-up of 59.5 months, the 5-year DFS and OS rates were 66% and 79%, respectively. Multivariable analysis demonstrated that ΔSUVmax ≥ 50% was associated with favorable DFS (hazard ratio [HR], 2.56; 95% confidence interval [CI], 1.14 to 5.77) and OS (HR, 5.14; 95% CI, 1.55 to 17.01). Patients with ΔSUVmax ≥ 50% (n=87) showed better DFS and OS than those with ΔSUVmax < 50% (n=29) (DFS, 76% vs. 35%, p < 0.001; OS, 90% vs. 41%, p < 0.001, respectively). Adenocarcinoma was frequently observed in ΔSUVmax < 50% compared to ΔSUVmax ≥ 50% (27.6% vs. 10.3%, p=0.003). In addition, models incorporating metabolic parameters showed improved accuracy for predicting DFS (p=0.012) and OS (p=0.004) than models with clinicopathologic factors.
Conclusion
Changes in metabolic parameters, especially those in SUVmax by > 50%, can help improve survival outcome predictions for patients with cervical cancer treated with definitive RT.

Citations

Citations to this article as recorded by  
  • Personalized strategies for brachytherapy of cervix cancer
    Guillaume Camprodon, Alexandra Gabro, Zineb El Ayachi, Supriya Chopra, Remi Nout, Philippe Maingon, Cyrus Chargari
    Cancer/Radiothérapie.2024; 28(6-7): 610.     CrossRef
  • Brachytherapy for cervical cancer: from intracavitary to interstitial technique
    Xiaojing Yang, Hanru Ren, Zhen Li, Jie Fu
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Application of three-dimensional multi-imaging combination in brachytherapy of cervical cancer
    Zhaoming Zhang, Ning Zhang, Guanghui Cheng
    La radiologia medica.2023; 128(5): 588.     CrossRef
  • MRI- and PET-Based Assessment of Radiological and Clinical Factors Associated With Cervical Cancer Response to External Beam Radiation Therapy
    Arun G Paul, Steven Miller, Lance K Heilbrun, Daryn W Smith
    Cureus.2022;[Epub]     CrossRef
  • 6,236 View
  • 174 Download
  • 5 Web of Science
  • 4 Crossref
Close layer
Pretreatment Lymph Node Metastasis as a Prognostic Significance in Cervical Cancer: Comparison between Disease Status
Soo Young Jeong, Hyea Park, Myeong Seon Kim, Jun Hyeok Kang, E Sun Paik, Yoo-Young Lee, Tae Joong Kim, Jeong Won Lee, Byoung-Gie Kim, Duk Soo Bae, Chel Hun Choi
Cancer Res Treat. 2020;52(2):516-523.   Published online October 29, 2019
DOI: https://doi.org/10.4143/crt.2019.328
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Lymph node metastasis (LNM) is the most significant prognostic factor in cervical cancer that was recently incorporated into the International Federation of Gynecology and Obstetrics (FIGO) staging system. This study was performed to evaluate whether the prognostic significance of LNM differs according to disease status.
Materials and Methods
Patients with FIGO stage IB or higher cervical cancer who had pretreatment computed tomography and/or magnetic resonance imaging studies as well as long-term follow-up were enrolled in this retrospective study. The hazard ratio (HR) of Cox regression was used to determine the prognostic significance of LNM. The HRs were compared between the different tumor groups (based on stage, histology, tumor size, primary treatment, age, parametrium involvement, and lymphovascular space invasion).
Results
A total of 970 patients treated between January 1999 and December 2007 were included. The pretreatment LNM had prognostic significance in patients with stage IB1/IIA (HR for progression-free survival 2.10, p=0.001; HR for overall survival 1.99, p=0.005). However, the significance gradually decreased or disappeared with advancing stages. Similarly, the prognostic significance of the pretreatment LNM decreased with advancing disease status, including old age, parametrial involvement or lymphovascular space involvement. In contrast, the tumor size was associated with the prognostic significance of LNM with advancing status. The significance of the clinical LNM did not reflect the significance of the clinical stage. In contrast, the tumor size, parametrial involvement, and significance of the pathologic LNM reflected the clinical stage.
Conclusion
In patients with cervical cancer, pretreatment LNM on imaging has different clinical significance depending on the tumor status.

Citations

Citations to this article as recorded by  
  • Predicting the risk of lymph node metastasis in colon cancer: development and validation of an online dynamic nomogram based on multiple preoperative data
    Longlian Deng, Lemuge Che, Haibin Sun, Riletu En, Bowen Ha, Tao Liu, Tengqi Wang, Qiang Xu
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Complete remission of a high-risk, locally advanced cervical cancer with para-aortic lymph node metastases treated with first-line tislelizumab plus bevacizumab combined with chemotherapy followed by radiotherapy with maintenance therapy: a case report
    Juan Lang, Qianqian Liu, Rong Ji, Miao Qiu, Siben Wang, Qingmeng Liu, Dapeng Li, Ping Chen, Zhongkui Xiong
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Application of CT in predicting lymph node metastasis in cervical cancer and construction of a preoperative nomogram
    Xiao Meng, Siyu Song, Ke Li, Yajie Duan, Jiayuan Zhong, Jiawei Wang, Shichao Han
    Scientific Reports.2025;[Epub]     CrossRef
  • Development of cervical intraepithelial neoplasia and invasive cervical cancer due to oxidative stress
    Amir Asotić, Memić Asotić, Muhamed Memić, Kerim Asotić, Amra Asotić
    Sanamed.2024; 19(1): 39.     CrossRef
  • Investigating and Analyzing Prognostic Factors and Their Impact on Recurrent Cervical Cancers
    Ashish Uke, Shweta B Dahake, Anurag Luharia, Monika Luharia, Gaurav V Mishra, Chanrashekhar Mahakalkar
    Cureus.2024;[Epub]     CrossRef
  • Based on 3D-PDU and clinical characteristics nomogram for prediction of lymph node metastasis and lymph-vascular space invasion of early cervical cancer preoperatively
    Shuang Dong, Yan-Qing Peng, Ya-Nan Feng, Xiao-Ying Li, Li-Ping Gong, Shuang Zhang, Xiao-Shan Du, Li-Tao Sun
    BMC Women's Health.2024;[Epub]     CrossRef
  • Recent Advances in Cervical Cancer Management: A Review on Novel Prognostic Factors in Primary and Recurrent Tumors
    Angela Santoro, Frediano Inzani, Giuseppe Angelico, Damiano Arciuolo, Emma Bragantini, Antonio Travaglino, Michele Valente, Nicoletta D’Alessandris, Giulia Scaglione, Stefania Sfregola, Alessia Piermattei, Federica Cianfrini, Paola Roberti, Gian Franco Za
    Cancers.2023; 15(4): 1137.     CrossRef
  • Identification of lymph node metastasis in pre‐operation cervical cancer patients by weakly supervised deep learning from histopathological whole‐slide biopsy images
    Qingqing Liu, Nan Jiang, Yiping Hao, Chunyan Hao, Wei Wang, Tingting Bian, Xiaohong Wang, Hua Li, Yan zhang, Yanjun Kang, Fengxiang Xie, Yawen Li, XuJi Jiang, Yuan Feng, Zhonghao Mao, Qi Wang, Qun Gao, Wenjing Zhang, Baoxia Cui, Taotao Dong
    Cancer Medicine.2023; 12(17): 17952.     CrossRef
  • Roles of DWI and T2-weighted MRI volumetry in the evaluation of lymph node metastasis and lymphovascular invasion of stage IB–IIA cervical cancer
    Y. Wang, X. Chen, H. Pu, Y. Yuan, S. Li, G. Chen, Y. Liu, H. Li
    Clinical Radiology.2022; 77(3): 224.     CrossRef
  • Risk Factor Assessment of Lymph Node Metastasis in Patients With FIGO Stage IB1 Cervical Cancer
    Mu Xu, Xiaoyan Xie, Liangzhi Cai, Yongjin Xie, Qiao Gao, Pengming Sun
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Intravoxel Incoherent Motion (IVIM) MR Quantification in Locally Advanced Cervical Cancer (LACC): Preliminary Study on Assessment of Tumor Aggressiveness and Response to Neoadjuvant Chemotherapy
    Miriam Dolciami, Silvia Capuani, Veronica Celli, Alessandra Maiuro, Angelina Pernazza, Innocenza Palaia, Violante Di Donato, Giusi Santangelo, Stefania Maria Rita Rizzo, Paolo Ricci, Carlo Della Rocca, Carlo Catalano, Lucia Manganaro
    Journal of Personalized Medicine.2022; 12(4): 638.     CrossRef
  • The prognostic significance of pretreatment squamous cell carcinoma antigen levels in cervical cancer patients treated by concurrent chemoradiation therapy and a comparison of dosimetric outcomes and clinical toxicities between tomotherapy and volumetric
    Yuan-Kai Cheng, Shih-Hsun Kuo, Heng-Hsuan Yen, Jing-Hu Wu, Yu-Chieh Chen, Ming-Yii Huang
    Radiation Oncology.2022;[Epub]     CrossRef
  • What MRI-based tumor size measurement is best for predicting long-term survival in uterine cervical cancer?
    Njål Lura, Kari S. Wagner-Larsen, David Forsse, Jone Trovik, Mari K. Halle, Bjørn I. Bertelsen, Øyvind Salvesen, Kathrine Woie, Camilla Krakstad, Ingfrid S. Haldorsen
    Insights into Imaging.2022;[Epub]     CrossRef
  • Clinical value of MRI, serum SCCA, and CA125 levels in the diagnosis of lymph node metastasis and para-uterine infiltration in cervical cancer
    Chao Ran, Jian Sun, Yunhui Qu, Na Long
    World Journal of Surgical Oncology.2021;[Epub]     CrossRef
  • A Novel Four-Gene Prognostic Signature as a Risk Biomarker in Cervical Cancer
    Jun Wang, Hua Zheng, Yatian Han, Geng Wang, Yanbin Li, Cuida Meng
    International Journal of Genomics.2020; 2020: 1.     CrossRef
  • 10,618 View
  • 225 Download
  • 15 Web of Science
  • 15 Crossref
Close layer
Molecular Signature for Lymphatic Invasion Associated with Survival of Epithelial Ovarian Cancer
E Sun Paik, Hyun Jin Choi, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Duk-Soo Bae, Chel Hun Choi
Cancer Res Treat. 2018;50(2):461-473.   Published online May 22, 2017
DOI: https://doi.org/10.4143/crt.2017.104
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We aimed to develop molecular classifier that can predict lymphatic invasion and their clinical significance in epithelial ovarian cancer (EOC) patients.
Materials and Methods
We analyzed gene expression (mRNA, methylated DNA) in data from The Cancer Genome Atlas. To identify molecular signatures for lymphatic invasion, we found differentially expressed genes. The performance of classifier was validated by receiver operating characteristics analysis, logistic regression, linear discriminant analysis (LDA), and support vector machine (SVM). We assessed prognostic role of classifier using random survival forest (RSF) model and pathway deregulation score (PDS). For external validation,we analyzed microarray data from 26 EOC samples of Samsung Medical Center and curatedOvarianData database.
Results
We identified 21 mRNAs, and seven methylated DNAs from primary EOC tissues that predicted lymphatic invasion and created prognostic models. The classifier predicted lymphatic invasion well, which was validated by logistic regression, LDA, and SVM algorithm (C-index of 0.90, 0.71, and 0.74 for mRNA and C-index of 0.64, 0.68, and 0.69 for DNA methylation). Using RSF model, incorporating molecular data with clinical variables improved prediction of progression-free survival compared with using only clinical variables (p < 0.001 and p=0.008). Similarly, PDS enabled us to classify patients into high-risk and low-risk group, which resulted in survival difference in mRNA profiles (log-rank p-value=0.011). In external validation, gene signature was well correlated with prediction of lymphatic invasion and patients’ survival.
Conclusion
Molecular signature model predicting lymphatic invasion was well performed and also associated with survival of EOC patients.

Citations

Citations to this article as recorded by  
  • Identifying Stage II Colorectal Cancer Recurrence Associated Genes by Microarray Meta-Analysis and Building Predictive Models with Machine Learning Algorithms
    Wei Lu, Xiang Pan, Siqi Dai, Dongliang Fu, Maxwell Hwang, Yingshuang Zhu, Lina Zhang, Jingsun Wei, Xiangxing Kong, Jun Li, Qian Xiao, Kefeng Ding, Quan Cheng
    Journal of Oncology.2021; 2021: 1.     CrossRef
  • 10,314 View
  • 249 Download
  • 5 Web of Science
  • 1 Crossref
Close layer
An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021)
Shin-Wha Lee, Yong-Man Kim, Chi Heum Cho, Young Tae Kim, Seok Mo Kim, Soo Young Hur, Jae-Hoon Kim, Byoung-Gie Kim, Seung-Cheol Kim, Hee-Sug Ryu, Soon Beom Kang
Cancer Res Treat. 2018;50(1):195-203.   Published online March 21, 2017
DOI: https://doi.org/10.4143/crt.2016.376
AbstractAbstract PDFPubReaderePub
Purpose
Genexol-PM is a biodegradable cremophor EL–free polymeric micelle formulation of paclitaxel. Here,we compared efficacy and safety of Genexol-PM plus carboplatin versus Genexol plus carboplatin for ovarian cancer treatment.
Materials and Methods
In this multicenter, randomized, phase II study, patients with International Federation of Gynecology and Obstetrics IC-IV epithelial ovarian cancer were randomly assigned (1:1) to receive Genexol-PM 260 mg/m2 or Genexol 175 mg/m2 with 5 area under the curve carboplatin every 3weeks (6 cycles). The primary endpointwas the carbohydrate antigen 125 and Response Evaluation Criteria In Solid Tumor composite overall response rate (ORR).
Results
Of 131 enrolled patients, 98 were included in intention-to-treat analysis. Mean dosages were 260.00±0.00 mg/m2 Genexol-PM or 174.24±3.81 mg/m2 Genexol. Median followup was 18.0 months (range, 6.1 to 33.8 months). ORR was 88.0% (95% confidence interval [CI], 80.4 to 95.6) with Genexol-PM, and 77.1% (95% CI, 67.1 to 87.1) with Genexol (noninferiority threshold, 16.3%). Median time to progression was 14.8 months (95% CI, 11.3 to 20.2) with Genexol-PM and 15.4 months (95% CI, 13.2 to 29.6) with Genexol (p=0.550). Overall, six patients died. Neutropenia was the most common toxicity (incidences of 86.0% vs. 77.1%, p=0.120). Peripheral neuropathy incidences were 84.0% versus 64.6% (p= 0.148). Peripheral neuropathy of ≥ grade 3 occurred in one patient receiving Genexol. All toxicities were manageable.
Conclusion
Genexol-PM plus carboplatin as first-line treatment in patients with epithelial ovarian cancer demonstrated non-inferior efficacy and well-tolerated toxicities compared with the standard paclitaxel regimen. Further studies are warranted to optimize the dose and schedule, and to investigate long-term outcomes.

Citations

Citations to this article as recorded by  
  • Medical nanoscale materials for virus-induced cervical cancer therapeutic modalities: For targeting delivery
    Adane Adugna, Mamaru Getinet, Gashaw Azanaw Amare, Mohammed Jemal
    OpenNano.2025; 21: 100221.     CrossRef
  • From Pioneering Discoveries to Innovative Therapies: A Journey Through the History and Advancements of Nanoparticles in Breast Cancer Treatment
    Fatemah Basingab, Omniah Alshahrani, Ibtehal Alansari, Nada Almarghalani, Nada Alshelali, Abeer Alsaiary, Najwa Alharbi, Kawther Zaher
    Breast Cancer: Targets and Therapy.2025; Volume 17: 27.     CrossRef
  • PD-L1-Targeting Nanoparticles for the Treatment of Triple-Negative Breast Cancer: A Preclinical Model
    Wendy K. Nevala, Liyi Geng, Hui Xie, Noah A. Stueven, Svetomir N. Markovic
    International Journal of Molecular Sciences.2025; 26(7): 3295.     CrossRef
  • Nano-drug delivery systems based on biodegradable polymers for the therapy of gynecological malignancies
    Keer Jin, Hanxue Zhang, Yuwei Yang, Yan Gao
    International Journal of Polymeric Materials and Polymeric Biomaterials.2024; 73(14): 1262.     CrossRef
  • Dual stimuli-responsive polymeric prodrug consisting of reversible covalent bonded celastrol for tumor targeted delivery
    Jiangtao Su, Meng Rao, Heshuang Dai, Le Cai, Fan Ye, Lu Ye, Yuchen Hu, Ban Chen, Xiaoxia Guo
    Macromolecular Research.2024; 32(2): 173.     CrossRef
  • Designing nanodiscs as versatile platforms for on-demand therapy
    Qianwen Mu, Haolan Deng, Xiaoyu An, Gang Liu, Chao Liu
    Nanoscale.2024; 16(5): 2220.     CrossRef
  • Innovative strategies for effective paclitaxel delivery: Recent developments and prospects
    Sławomir Wileński, Agnieszka Koper, Paulina Śledzińska, Marek Bebyn, Krzysztof Koper
    Journal of Oncology Pharmacy Practice.2024; 30(2): 367.     CrossRef
  • Platelet-derived drug delivery systems: Pioneering treatment for cancer, cardiovascular diseases, infectious diseases, and beyond
    Yalan Zhu, Lingling Xu, Yong Kang, Qinzhen Cheng, Yiling He, Xiaoyuan Ji
    Biomaterials.2024; 306: 122478.     CrossRef
  • Nanoparticle-Based Immunotherapy for Reversing T-Cell Exhaustion
    Fei Li, Yahong Wang, Dandan Chen, Yunjie Du
    International Journal of Molecular Sciences.2024; 25(3): 1396.     CrossRef
  • Delivery of Nucleic Acid Drugs for Tumor Therapy: Opportunities and Challenges
    Dandan Sun, Wenjia Tan, Jianan Zhao, Yafei Tian, Siqi Li, Zhiqi Zhang, Xinzhe Dong, Xiaonan Liu, Na Liu, Ping Jiao, Jie Ma
    Fundamental Research.2024;[Epub]     CrossRef
  • Effect of high-dose polymeric nanoparticle micellar paclitaxel on improved progression-free survival in patients with optimally resected stage III or IV high-grade carcinoma of the ovary: a prospective cohort study with historical controls
    Soo Jin Park, Joo-Hyuk Son, Tae-Wook Kong, Suk-Joon Chang, Hee Seung Kim
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Co-Assembly of Cancer Drugs with Cyclo-HH Peptides: Insights from Simulations and Experiments
    Anastasia Vlachou, Vijay Bhooshan Kumar, Om Shanker Tiwari, Sigal Rencus-Lazar, Yu Chen, Busra Ozguney, Ehud Gazit, Phanourios Tamamis
    ACS Applied Bio Materials.2024; 7(4): 2309.     CrossRef
  • Biomarkers in Ovarian Cancer: Towards Personalized Medicine
    Carlos López-Portugués, María Montes-Bayón, Paula Díez
    Proteomes.2024; 12(1): 8.     CrossRef
  • Internalization of transferrin-tagged Myxococcus xanthus encapsulins into mesenchymal stem cells
    Anna N. Gabashvili, Natalya A. Alexandrushkina, Elizaveta N. Mochalova, Daria V. Goliusova, Ekaterina N. Sapozhnikova, Pavel I. Makarevich, Petr I. Nikitin
    Experimental Biology and Medicine.2024;[Epub]     CrossRef
  • Functionalized Polymeric Micelles for Targeted Cancer Therapy: Steps from Conceptualization to Clinical Trials
    Ana Serras, Célia Faustino, Lídia Pinheiro
    Pharmaceutics.2024; 16(8): 1047.     CrossRef
  • Polyesters and Polyester Nano- and Microcarriers for Drug Delivery
    Stanislaw Slomkowski, Teresa Basinska, Mariusz Gadzinowski, Damian Mickiewicz
    Polymers.2024; 16(17): 2503.     CrossRef
  • Nanotheranostics for gynecological cancers: a path forward for Africa
    Mutia Kehwalla Aza, Anavami Suberu, Mahmood Balogun, Goodness Adegbola, Mohamed Alie Sankoh, Thomas Oyediran, Nicholas Aderinto, Gbolahan Olatunji, Emmanuel Kokori, Chinonyelum Emmanuel Agbo
    Medical Oncology.2024;[Epub]     CrossRef
  • Pharmacokinetic behaviors of soft nanoparticulate formulations of chemotherapeutics
    Mahua Sarkar, Yang Wang, Oscar Ekpenyong, Dong Liang, Huan Xie
    WIREs Nanomedicine and Nanobiotechnology.2023;[Epub]     CrossRef
  • Cancer treatment and toxicity outlook of nanoparticles
    Neetika, Mamta Sharma, Pankaj Thakur, Paras Gaur, Gokana Mohana Rani, Sarvesh Rustagi, Rishi Kumar Talreja, Vishal Chaudhary
    Environmental Research.2023; 237: 116870.     CrossRef
  • Efficacy and Safety of Nanopaclitaxel Formulation for Cancer Treatment: Evidence From Randomized Clinical Trials
    Xiangmin Deng, Xiaoqin Huang, Xiaoyan Dong, Genxiang Mao, Wenmin Xing
    Nanomedicine.2023; 18(10): 833.     CrossRef
  • Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers
    Tetiana Korzun, Abraham S. Moses, Parham Diba, Ariana L. Sattler, Brennan Olson, Olena R. Taratula, Tanja Pejovic, Daniel L. Marks, Oleh Taratula
    Small.2023;[Epub]     CrossRef
  • Nanoprobe-based molecular imaging for tumor stratification
    Xianbin Ma, Mingchuan Mao, Jiaqi He, Chao Liang, Hai-Yan Xie
    Chemical Society Reviews.2023; 52(18): 6447.     CrossRef
  • Magic shotgun over magic bullet for treatment of ovarian cancer via polymeric nanoparticles
    Bakr Ahmed, Anuradha Sharma, Zakiya Usmani, Garima Sharma, Joga Singh, Radhika Yadav, Indu Sharma, Indu Pal Kaur
    Journal of Drug Delivery Science and Technology.2023; 88: 104945.     CrossRef
  • Safety and Tolerability of Weekly Genexol-PM, a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel, with Carboplatin in Gynecologic Cancer: A Phase I Study
    So Hyun Nam, Shin-Wha Lee, Young-Jae Lee, Yong Man Kim
    Cancer Research and Treatment.2023; 55(4): 1346.     CrossRef
  • Effective Cancer Management: Inimitable Role of Phytochemical Based Nano- Formulations
    Aman Upaganlawar, Satish Polshettiwar, Sushil Raut, Amol Tagalpallewar, Vishal Pande
    Current Drug Metabolism.2022; 23(11): 869.     CrossRef
  • Comparison of triblock copolymeric micelles based on α- and ε-poly(L-lysine): a Cornelian choice
    Franck Marquet, Viorica Patrulea, Gerrit Borchard
    Polymer Journal.2022; 54(2): 199.     CrossRef
  • Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic
    Vladimir A. Ljubimov, Arshia Ramesh, Saya Davani, Moise Danielpour, Joshua J. Breunig, Keith L. Black
    Advanced Drug Delivery Reviews.2022; 181: 114033.     CrossRef
  • Nanocarriers targeting the diseases of the pancreas
    Nurbanu Demirtürk, Erem Bilensoy
    European Journal of Pharmaceutics and Biopharmaceutics.2022; 170: 10.     CrossRef
  • The development and progress of nanomedicine for esophageal cancer diagnosis and treatment
    Xiaokun Li, Lingmin Chen, Siyuan Luan, Jianfeng Zhou, Xin Xiao, Yushang Yang, Chengyi Mao, Pinhao Fang, Longqi Chen, Xiaoxi Zeng, Huile Gao, Yong Yuan
    Seminars in Cancer Biology.2022; 86: 873.     CrossRef
  • Beyond separation: Membranes towards medicine
    Ying Xie, Zhenyu Chu, Wanqin Jin
    Journal of Membrane Science Letters.2022; 2(1): 100020.     CrossRef
  • Modulation of TLR/NF-κB/NLRP Signaling by Bioactive Phytocompounds: A Promising Strategy to Augment Cancer Chemotherapy and Immunotherapy
    Sajad Fakhri, Seyed Zachariah Moradi, Akram Yarmohammadi, Fatemeh Narimani, Carly E. Wallace, Anupam Bishayee
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Gold Nanorods for Drug and Gene Delivery: An Overview of Recent Advancements
    Atieh Jahangiri-Manesh, Marziyeh Mousazadeh, Shirinsadat Taji, Abbas Bahmani, Atefeh Zarepour, Ali Zarrabi, Esmaeel Sharifi, Mostafa Azimzadeh
    Pharmaceutics.2022; 14(3): 664.     CrossRef
  • Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story
    Ekati Drakopoulou, Nicholas P. Anagnou, Kalliopi I. Pappa
    Cancers.2022; 14(13): 3238.     CrossRef
  • Engineering nanosystems to overcome barriers to cancer diagnosis and treatment
    Suhaila O. Alhaj-Suliman, Emad I. Wafa, Aliasger K. Salem
    Advanced Drug Delivery Reviews.2022; 189: 114482.     CrossRef
  • Metabolic Signatures of Surface-Modified Poly(lactic-co-glycolic acid) Nanoparticles in Differentiated THP-1 Cells Derived with Liquid Chromatography-Mass Spectrometry-based Metabolomics
    Mohammad A. Al-natour, Salah Abdelrazig, Amir M. Ghaemmaghami, Cameron Alexander, Dong-Hyun Kim
    ACS Omega.2022; 7(33): 28806.     CrossRef
  • Pathogen-derived peptides in drug targeting and its therapeutic approach
    Seok-Jun Mun, Euni Cho, Jae-Sung Kim, Chul-Su Yang
    Journal of Controlled Release.2022; 350: 716.     CrossRef
  • Application of single and cooperative different delivery systems for the treatment of intervertebral disc degeneration
    Zongtai Liu, Changfeng Fu
    Frontiers in Bioengineering and Biotechnology.2022;[Epub]     CrossRef
  • Engineering the Tumor Immune Microenvironment through Minimally Invasive Interventions
    Koustav Pal, Rahul A. Sheth
    Cancers.2022; 15(1): 196.     CrossRef
  • Nanoparticle delivery systems to combat drug resistance in ovarian cancer
    Emily M. Miller, Timothy M. Samec, Angela A. Alexander-Bryant
    Nanomedicine: Nanotechnology, Biology and Medicine.2021; 31: 102309.     CrossRef
  • Engineering precision nanoparticles for drug delivery
    Michael J. Mitchell, Margaret M. Billingsley, Rebecca M. Haley, Marissa E. Wechsler, Nicholas A. Peppas, Robert Langer
    Nature Reviews Drug Discovery.2021; 20(2): 101.     CrossRef
  • Clinical applications of nanomedicines in lung cancer treatment
    Mohammad Norouzi, Pierre Hardy
    Acta Biomaterialia.2021; 121: 134.     CrossRef
  • Lyophilization stabilizes clinical‐stage core‐crosslinked polymeric micelles to overcome cold chain supply challenges
    Tarun Ojha, Qizhi Hu, Claudio Colombo, Jan Wit, Michiel van Geijn, Mies J. van Steenbergen, Mahsa Bagheri, Hiltrud Königs‐Werner, Eva Miriam Buhl, Ruchi Bansal, Yang Shi, Wim E. Hennink, Gert Storm, Cristianne J. F. Rijcken, Twan Lammers
    Biotechnology Journal.2021;[Epub]     CrossRef
  • Development of next generation nanomedicine-based approaches for the treatment of cancer: we've barely scratched the surface
    Shannon R. Tracey, Peter Smyth, Caroline J. Barelle, Christopher J. Scott
    Biochemical Society Transactions.2021; 49(5): 2253.     CrossRef
  • Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies
    Ellen Cusano, Chelsea Wong, Eddy Taguedong, Marcus Vaska, Tasnima Abedin, Nancy Nixon, Safiya Karim, Patricia Tang, Daniel Y. C. Heng, Doreen Ezeife
    Current Oncology.2021; 28(6): 4894.     CrossRef
  • Engineering Considerations to Produce Bioactive Compounds from Plant Cell Suspension Culture in Bioreactors
    Elizabeth Alejandra Motolinía-Alcántara, Carlos Omar Castillo-Araiza, Mario Rodríguez-Monroy, Angélica Román-Guerrero, Francisco Cruz-Sosa
    Plants.2021; 10(12): 2762.     CrossRef
  • Clinical applications of nanomedicine in cancer therapy
    Mohammad Norouzi, Mehrnaz Amerian, Mahshid Amerian, Fatemeh Atyabi
    Drug Discovery Today.2020; 25(1): 107.     CrossRef
  • Targeting and extending the eukaryotic druggable genome with natural products: cytoskeletal targets of natural products
    April L. Risinger, Lin Du
    Natural Product Reports.2020; 37(5): 634.     CrossRef
  • Improvement of Paclitaxel-Associated Adverse Reactions (ADRs) via the Use of Nano-Based Drug Delivery Systems: A Systematic Review and Network Meta-Analysis


    Pi-Ling Chou, Ya-Ping Huang, Meng-Hsuan Cheng, Kun-Ming Rau, Yi-Ping Fang
    International Journal of Nanomedicine.2020; Volume 15: 1731.     CrossRef
  • Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval
    Duhyeong Hwang, Jacob D. Ramsey, Alexander V. Kabanov
    Advanced Drug Delivery Reviews.2020; 156: 80.     CrossRef
  • Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy
    Yuan Li, Yan Gao, Xi Zhang, Hongyan Guo, Huile Gao
    International Journal of Pharmaceutics.2020; 591: 119986.     CrossRef
  • Synthesis of PCL–PEG–PCL Triblock Copolymer via Organocatalytic Ring-Opening Polymerization and Its Application as an Injectable Hydrogel—An Interdisciplinary Learning Trial
    Kaiting Wu, Lin Yu, Jiandong Ding
    Journal of Chemical Education.2020; 97(11): 4158.     CrossRef
  • Phytochemical-Based Nanomedicine for Advanced Cancer Theranostics: Perspectives on Clinical Trials to Clinical Use


    Madhusmita Dhupal, Devasish Chowdhury
    International Journal of Nanomedicine.2020; Volume 15: 9125.     CrossRef
  • Synthesis and anti-cancer evaluation of folic acid-peptide- paclitaxel conjugates for addressing drug resistance
    Yuxuan Dai, Xingguang Cai, Xinzhou Bi, Chunxia Liu, Na Yue, Ying Zhu, Jiaqi Zhou, Mian Fu, Wenlong Huang, Hai Qian
    European Journal of Medicinal Chemistry.2019; 171: 104.     CrossRef
  • A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
    Bhumsuk Keam, Keun-Wook Lee, Se-Hoon Lee, Jin-Soo Kim, Jin Ho Kim, Hong-Gyun Wu, Keun-Yong Eom, Suzy Kim, Soon-Hyun Ahn, Eun-Jae Chung, Seong Keun Kwon, Woo-Jin Jeong, Young Ho Jung, Ji-Won Kim, Dae Seog Heo
    The Oncologist.2019; 24(6): 751.     CrossRef
  • Polymeric Hybrid Nanomicelles for Cancer Theranostics: An Efficient and Precise Anticancer Strategy for the Codelivery of Doxorubicin/miR-34a and Magnetic Resonance Imaging
    Xiaoxue Xie, Yu Chen, Zhongyuan Chen, Yi Feng, Jing Wang, Tingting Li, Shun Li, Xiang Qin, Chunhui Wu, Chuan Zheng, Jie Zhu, Fengming You, Yiyao Liu, Hong Yang
    ACS Applied Materials & Interfaces.2019; 11(47): 43865.     CrossRef
  • Micellar paclitaxel in the treatment of patients with tumors of the female reproductive system
    A. G. Kedrova, S. E. Krasilnikov, D. A. Astakhov, V. V. Kosyy
    Tumors of female reproductive system.2019; 15(3): 37.     CrossRef
  • Improving Drug Delivery of Micellar Paclitaxel against Non‐Small Cell Lung Cancer by Coloading Itraconazole as a Micelle Stabilizer and a Tumor Vascular Manipulator
    Ling Zhang, Zhengsheng Liu, Chao Kong, Chun Liu, Kuan Yang, Huijun Chen, Jinfeng Huang, Feng Qian
    Small.2018;[Epub]     CrossRef
  • 13,924 View
  • 362 Download
  • 60 Web of Science
  • 57 Crossref
Close layer
Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies
Eun Jin Heo, Young Jae Cho, William Chi Cho, Ji Eun Hong, Hye-Kyung Jeon, Doo-Yi Oh, Yoon-La Choi, Sang Yong Song, Jung-Joo Choi, Duk-Soo Bae, Yoo-Young Lee, Chel Hun Choi, Tae-Joong Kim, Woong-Yang Park, Byoung-Gie Kim, Jeong-Won Lee
Cancer Res Treat. 2017;49(4):915-926.   Published online January 4, 2017
DOI: https://doi.org/10.4143/crt.2016.322
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Patient-derived tumor xenografts (PDXs) can provide more reliable information about tumor biology than cell line models. We developed PDXs for epithelial ovarian cancer (EOC) that have histopathologic and genetic similarities to the primary patient tissues and evaluated their potential for use as a platform for translational EOC research.
Materials and Methods
We successfully established PDXs by subrenal capsule implantation of primary EOC tissues into female BALB/C-nude mice. The rate of successful PDX engraftment was 48.8% (22/45 cases). Hematoxylin and eosin staining and short tandem repeat analysis showed histopathological and genetic similarity between the PDX and primary patient tissues.
Results
Patients whose tumors were successfully engrafted in mice had significantly inferior overall survival when compared with those whose tumors failed to engraft (p=0.040). In preclinical tests of this model, we found that paclitaxel-carboplatin combination chemotherapy significantly deceased tumor weight in PDXs compared with the control treatment (p=0.013). Moreover, erlotinib treatment significantly decreased tumor weight in epidermal growth factor receptor–overexpressing PDX with clear cell histology (p=0.023).
Conclusion
PDXs for EOC with histopathological and genetic stability can be efficiently developed by subrenal capsule implantation and have the potential to provide a promising platform for future translational research and precision medicine for EOC.

Citations

Citations to this article as recorded by  
  • Patient-derived xenograft models: Current status, challenges, and innovations in cancer research
    Min qi Liu, Xiaoping Yang
    Genes & Diseases.2025; : 101520.     CrossRef
  • Establishment and characterization of ovarian clear cell carcinoma patient-derived xenografts
    Joseph J. Caumanns, Shang Li, Gert J. Meersma, Evelien W. Duiker, Ate G. J. van der Zee, G. Bea A. Wisman, Steven de Jong
    Scientific Reports.2025;[Epub]     CrossRef
  • The anti-tumor effects of AZD4547 on ovarian cancer cells: differential responses based on c-Met and FGF19/FGFR4 expression
    Yoo-Young Lee, Ji-Yoon Ryu, Young-Jae Cho, Ju-Yeon Choi, Jung-Joo Choi, Chel Hun Choi, Jason K. Sa, Jae Ryoung Hwang, Jeong-Won Lee
    Cancer Cell International.2024;[Epub]     CrossRef
  • Creation and Validation of Patient-Derived Cancer Model Using Peritoneal and Pleural Effusion in Patients with Advanced Ovarian Cancer: An Early Experience
    Ruri Nishie, Tomohito Tanaka, Kensuke Hirosuna, Shunsuke Miyamoto, Hikaru Murakami, Hiromitsu Tsuchihashi, Akihiko Toji, Shoko Ueda, Natsuko Morita, Sousuke Hashida, Atsushi Daimon, Shinichi Terada, Hiroshi Maruoka, Hiromi Konishi, Yuhei Kogata, Kohei Tan
    Journal of Clinical Medicine.2024; 13(9): 2718.     CrossRef
  • Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer
    Byumseok Koh, Ji-Yoon Ryu, Joseph J. Noh, Jae Ryoung Hwang, Jung-Joo Choi, Young-Jae Cho, Jiyoon Jang, Jeong Hyeon Jo, Kwangho Lee, Jeong-Won Lee
    Gynecologic Oncology.2024; 188: 60.     CrossRef
  • Recent advances in lung cancer organoid (tumoroid) research (Review)
    Qiang Zhang, Mingyang Zhang
    Experimental and Therapeutic Medicine.2024;[Epub]     CrossRef
  • Patient‐derived xenograft model in colorectal cancer basic and translational research
    Xiaofeng Liu, Zechang Xin, Kun Wang
    Animal Models and Experimental Medicine.2023; 6(1): 26.     CrossRef
  • Repurposing of triamterene as a histone deacetylase inhibitor to overcome cisplatin resistance in lung cancer treatment
    Kenneth K. W. To, Ka M. Cheung, William C. S. Cho
    Journal of Cancer Research and Clinical Oncology.2023; 149(10): 7217.     CrossRef
  • Anti-cancer effect of fenbendazole-incorporated PLGA nanoparticles in ovarian cancer
    Chi-Son Chang, Ji-Yoon Ryu, June-Kuk Choi, Young-Jae Cho, Jung-Joo Choi, Jae Ryoung Hwang, Ju-Yeon Choi, Joseph J. Noh, Chan Mi Lee, Ji Eun Won, Hee Dong Han, Jeong-Won Lee
    Journal of Gynecologic Oncology.2023;[Epub]     CrossRef
  • Molecular Biology of Pediatric and Adult Ovarian Germ Cell Tumors: A Review
    Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, Luiz Fernando Lopes
    Cancers.2023; 15(11): 2990.     CrossRef
  • Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice
    Mingtang Zeng, Zijing Ruan, Jiaxi Tang, Maozhu Liu, Chengji Hu, Ping Fan, Xinhua Dai
    Cancer Cell International.2023;[Epub]     CrossRef
  • Research Progress of PD-1/PD-L1 Inhibitors in Immunotherapy of Prostate Cancer
    佳慧 吴
    Advances in Clinical Medicine.2023; 13(06): 10496.     CrossRef
  • Ulipristal acetate, a selective progesterone receptor modulator, induces cell death via inhibition of STAT3/CCL2 signaling pathway in uterine sarcoma
    Jae Ryoung Hwang, Young-Jae Cho, Ji-Yoon Ryu, Ju-Yeon Choi, Jung-Joo Choi, Jason K. Sa, Hyun-Soo Kim, Jeong-Won Lee
    Biomedicine & Pharmacotherapy.2023; 168: 115792.     CrossRef
  • Establishment and characterization of a non-gestational choriocarcinoma patient-derived xenograft model
    Yukari Oda, Kaoru Niimi, Kosuke Yoshida, Satoshi Tamauchi, Akira Yokoi, Yuko Yasui, Yuki Nishiko, Mayu Shibata, Yusuke Shimizu, Masato Yoshihara, Yoshiki Ikeda, Nobuhisa Yoshikawa, Kimihiro Nishino, Eiko Yamamoto, Hiroaki Kajiyama
    BMC Cancer.2023;[Epub]     CrossRef
  • Identification of Prognostic Markers of Gynecologic Cancers Utilizing Patient-Derived Xenograft Mouse Models
    Ha-Yeon Shin, Eun-ju Lee, Wookyeom Yang, Hyo Sun Kim, Dawn Chung, Hanbyoul Cho, Jae-Hoon Kim
    Cancers.2022; 14(3): 829.     CrossRef
  • Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine
    Christine Yee, Kristie-Ann Dickson, Mohammed N. Muntasir, Yue Ma, Deborah J. Marsh
    Frontiers in Bioengineering and Biotechnology.2022;[Epub]     CrossRef
  • Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer
    Jung-In Shim, Ji-Yoon Ryu, Soo Young Jeong, Young-Jae Cho, Jung-Joo Choi, Jae Ryoung Hwang, Ju-Yeon Choi, Jason K. Sa, Jeong-Won Lee
    Gynecologic Oncology.2022; 165(2): 270.     CrossRef
  • Endometrial Cancer Patient-Derived Xenograft Models: A Systematic Review
    Tomohito Tanaka, Ruri Nishie, Shoko Ueda, Shunsuke Miyamoto, Sousuke Hashida, Hiromi Konishi, Shinichi Terada, Yuhei Kogata, Hiroshi Sasaki, Satoshi Tsunetoh, Kohei Taniguchi, Kazumasa Komura, Masahide Ohmichi
    Journal of Clinical Medicine.2022; 11(9): 2606.     CrossRef
  • Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application
    Alessandra Ciucci, Marianna Buttarelli, Anna Fagotti, Giovanni Scambia, Daniela Gallo
    Cellular and Molecular Life Sciences.2022;[Epub]     CrossRef
  • Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma
    Joseph J. Noh, Young-Jae Cho, Ji-Yoon Ryu, Jung-Joo Choi, Jae Ryoung Hwang, Ju-Yeon Choi, Jeong-Won Lee
    Clinical Cancer Research.2022; 28(17): 3850.     CrossRef
  • Harnessing preclinical models for the interrogation of ovarian cancer
    Tianyu Qin, Junpeng Fan, Funian Lu, Li Zhang, Chen Liu, Qiyue Xiong, Yang Zhao, Gang Chen, Chaoyang Sun
    Journal of Experimental & Clinical Cancer Research.2022;[Epub]     CrossRef
  • The Development of a Three-Dimensional Platform for Patient-Derived Ovarian Cancer Tissue Models: A Systematic Literature Review
    Lusine Sevinyan, Priyanka Gupta, Eirini Velliou, Thumuluru Kavitha Madhuri
    Cancers.2022; 14(22): 5628.     CrossRef
  • A Novel, Personalized Drug-Screening System for Platinum-Resistant Ovarian Cancer Patients: A Preliminary Clinical Report
    Yunke Huang, Jing Xu, Ke Li, Jing Wang, Yilin Dai, Yu Kang
    Cancer Management and Research.2021; Volume 13: 2849.     CrossRef
  • Establishment and preclinical application of a patient-derived xenograft model for uterine cancer
    Soo Young Jeong, Young-Jae Cho, Ji-Yoon Ryu, Jung-Joo Choi, Jae-Ryoung Hwang, Binnari Kim, Yoo-Young Lee, Hyun-Soo Kim, Jeong-Won Lee
    Gynecologic Oncology.2021; 162(1): 173.     CrossRef
  • Changes in Stem Cell Regulation and Epithelial Organisation during Carcinogenesis and Disease Progression in Gynaecological Malignancies
    Paula Cunnea, Christina Fotopoulou, Jennifer Ploski, Fabian Trillsch, Sven Mahner, Mirjana Kessler
    Cancers.2021; 13(13): 3349.     CrossRef
  • Patient-Derived Xenograft Models in Cervical Cancer: A Systematic Review
    Tomohito Tanaka, Ruri Nishie, Shoko Ueda, Shunsuke Miyamoto, Sousuke Hashida, Hiromi Konishi, Shinichi Terada, Yuhei Kogata, Hiroshi Sasaki, Satoshi Tsunetoh, Kohei Taniguchi, Kazumasa Komura, Masahide Ohmichi
    International Journal of Molecular Sciences.2021; 22(17): 9369.     CrossRef
  • Methodological aspects of creation of patient-derived tumor xenografts
    A S Goncharova, A N Shevchenko, I R Dashkova, A E Anisimov
    Kazan medical journal.2021; 102(5): 694.     CrossRef
  • The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis
    Jinseong Kim, Man Kyu Shim, Young-Jae Cho, Sangmin Jeon, Yujeong Moon, Jiwoong Choi, Jeongrae Kim, Jaewan Lee, Jeong-Won Lee, Kwangmeyung Kim
    Biomaterials.2021; 279: 121189.     CrossRef
  • Modeling the Tumor Microenvironment of Ovarian Cancer: The Application of Self-Assembling Biomaterials
    Ana Karen Mendoza-Martinez, Daniela Loessner, Alvaro Mata, Helena S. Azevedo
    Cancers.2021; 13(22): 5745.     CrossRef
  • Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research
    Magdalena Cybula, Lin Wang, Luyao Wang, Ana Luiza Drumond-Bock, Katherine M. Moxley, Doris M. Benbrook, Camille Gunderson-Jackson, Maria J. Ruiz-Echevarria, Resham Bhattacharya, Priyabrata Mukherjee, Magdalena Bieniasz
    Cancers.2021; 13(24): 6288.     CrossRef
  • Cytoplasmic expression of EGFR shRNA using a modified T7 autogene-based hybrid mRNA/DNA system induces long-term EGFR silencing and prolongs antitumor effects
    Sharmin Seraj, Young Jae Cho, Jeong-Won Lee, Hyung Jun Ahn
    Biochemical Pharmacology.2020; 171: 113735.     CrossRef
  • The fidelity of cancer cells in PDX models: Characteristics, mechanism and clinical significance
    Jiahao Shi, Yongyun Li, Renbing Jia, Xianqun Fan
    International Journal of Cancer.2020; 146(8): 2078.     CrossRef
  • KSP siRNA/paclitaxel-loaded PEGylated cationic liposomes for overcoming resistance to KSP inhibitors: Synergistic antitumor effects in drug-resistant ovarian cancer
    Jinju Lee, Young Jae Cho, Jeong-Won Lee, Hyung Jun Ahn
    Journal of Controlled Release.2020; 321: 184.     CrossRef
  • A patient‐derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma
    Tomoki Yamano, Shuji Kubo, Naohiro Tomita
    Cancer Medicine.2020; 9(10): 3337.     CrossRef
  • Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer
    E Sun Paik, Tae-Hyun Kim, Young Jae Cho, Jiyoon Ryu, Jung-Joo Choi, Yoo-Young Lee, Tae-Joong Kim, Chel-Hun Choi, Woo Young Kim, Jason K. Sa, Jin-Ku Lee, Byoung-Gie Kim, Duk-Soo Bae, Hee Dong Han, Hyung Jun Ahn, Jeong-Won Lee
    Scientific Reports.2020;[Epub]     CrossRef
  • A Biobank of Colorectal Cancer Patient-Derived Xenografts
    Suad M. Abdirahman, Michael Christie, Adele Preaudet, Marie C. U. Burstroem, Dmitri Mouradov, Belinda Lee, Oliver M. Sieber, Tracy L. Putoczki
    Cancers.2020; 12(9): 2340.     CrossRef
  • Epithelial/mesenchymal heterogeneity of high‐grade serous ovarian carcinoma samples correlates with miRNA let‐7 levels and predicts tumor growth and metastasis
    Evgeny Chirshev, Nozomi Hojo, Antonella Bertucci, Linda Sanderman, Anthony Nguyen, Hanmin Wang, Tise Suzuki, Emmanuel Brito, Shannalee R. Martinez, Christine Castañón, Saied Mirshahidi, Marcelo E. Vazquez, Pamela Wat, Kerby C. Oberg, Yevgeniya J. Ioffe, J
    Molecular Oncology.2020; 14(11): 2796.     CrossRef
  • Human-Derived Model Systems in Gynecological Cancer Research
    Kadi Lõhmussaar, Matteo Boretto, Hans Clevers
    Trends in Cancer.2020; 6(12): 1031.     CrossRef
  • Spontaneous and Induced Animal Models for Cancer Research
    Anca Onaciu, Raluca Munteanu, Vlad Cristian Munteanu, Diana Gulei, Lajos Raduly, Richard-Ionut Feder, Radu Pirlog, Atanas G. Atanasov, Schuyler S. Korban, Alexandru Irimie, Ioana Berindan-Neagoe
    Diagnostics.2020; 10(9): 660.     CrossRef
  • Anti-Cancer Activity of As4O6 and its Efficacy in a Series of Patient-Derived Xenografts for Human Cervical Cancer
    Joseph J. Noh, Myeong-Seon Kim, Young-Jae Cho, Soo-Young Jeong, Yoo-Young Lee, Ji-Yoon Ryu, Jung-Joo Choi, Illju Bae, Zhaoyan Wu, Byoung-Gie Kim, Jae Ryoung Hwang, Jeong-Won Lee
    Pharmaceutics.2020; 12(10): 987.     CrossRef
  • Patient-derived ovarian cancer explants: preserved viability and histopathological features in long-term agitation-based cultures
    Sofia Abreu, Fernanda Silva, Rita Mendes, Teresa F. Mendes, Marta Teixeira, Vítor E. Santo, Erwin R. Boghaert, Ana Félix, Catarina Brito
    Scientific Reports.2020;[Epub]     CrossRef
  • Chloroquine reverses chemoresistance via upregulation of p21WAF1/CIP1 and autophagy inhibition in ovarian cancer
    Jae Ryoung Hwang, Woo Young Kim, Young-Jae Cho, Ji-Yoon Ryu, Jung-Joo Choi, Soo Young Jeong, Myeong-Sun Kim, Ji Hye Kim, E. Sun Paik, Yoo-Young Lee, Hee-Dong Han, Jeong-Won Lee
    Cell Death & Disease.2020;[Epub]     CrossRef
  • Establishment of a Novel PDX Mouse Model and Evaluation of the Tumor Suppression Efficacy of Bortezomib Against Liposarcoma
    Eun Byeol Jo, Doopyo Hong, Young Sang Lee, Hyunjoo Lee, Jae Berm Park, Sung Joo Kim
    Translational Oncology.2019; 12(2): 269.     CrossRef
  • Platinum Resistance in Ovarian Cancer: Role of DNA Repair
    Giovanna Damia, Massimo Broggini
    Cancers.2019; 11(1): 119.     CrossRef
  • Establishment of patient‐derived xenograft model in ovarian cancer and its influence factors analysis
    Jianfa Wu, Yunxi Zheng, Qi Tian, Ming Yao, Xiaofang Yi
    Journal of Obstetrics and Gynaecology Research.2019; 45(10): 2062.     CrossRef
  • Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models
    Seiji Okada, Kulthida Vaeteewoottacharn, Ryusho Kariya
    Cells.2019; 8(8): 889.     CrossRef
  • Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research
    Akira Inoue, Angela K. Deem, Scott Kopetz, Timothy P. Heffernan, Giulio F. Draetta, Alessandro Carugo
    Cancers.2019; 11(9): 1321.     CrossRef
  • Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers
    Jason K. Sa, Jae Ryoung Hwang, Young-Jae Cho, Ji-Yoon Ryu, Jung-Joo Choi, Soo Young Jeong, Jihye Kim, Myeong Seon Kim, E. Sun Paik, Yoo-Young Lee, Chel Hun Choi, Tae-Joong Kim, Byoung-Gie Kim, Duk-Soo Bae, Yeri Lee, Nam-Gu Her, Yong Jae Shin, Hee Jin Cho,
    Genome Biology.2019;[Epub]     CrossRef
  • The latest animal models of ovarian cancer for novel drug discovery
    Elizabeth Magnotti, Wayne A. Marasco
    Expert Opinion on Drug Discovery.2018; 13(3): 249.     CrossRef
  • Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells
    Ugo Testa, Eleonora Petrucci, Luca Pasquini, Germana Castelli, Elvira Pelosi
    Medicines.2018; 5(1): 16.     CrossRef
  • NIRF Optical/PET Dual-Modal Imaging of Hepatocellular Carcinoma Using Heptamethine Carbocyanine Dye
    Caiqin Zhang, Yong Zhao, Ningning Zhao, Dengxu Tan, He Zhang, Xue Chen, Hai Zhang, Jiaze An, Changhong Shi, Mengbin Li
    Contrast Media & Molecular Imaging.2018; 2018: 1.     CrossRef
  • Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models
    Kyung Jin Eoh, Young Shin Chung, So Hyun Lee, Sun-Ae Park, Hee Jung Kim, Wookyeom Yang, In Ok Lee, Jung-Yun Lee, Hanbyoul Cho, Doo Byung Chay, Sunghoon Kim, Sang Wun Kim, Jae-Hoon Kim, Young Tae Kim, Eun Ji Nam
    Cancer Research and Treatment.2018; 50(3): 956.     CrossRef
  • CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer
    Yeongseon Byeon, Jeong-Won Lee, Whan Soo Choi, Ji Eun Won, Ga Hee Kim, Min Gi Kim, Tae In Wi, Jae Myeong Lee, Tae Heung Kang, In Duk Jung, Young-Jae Cho, Hyung Jun Ahn, Byung Cheol Shin, Young Joo Lee, Anil K. Sood, Hee Dong Han, Yeong-Min Park
    Cancer Research.2018; 78(21): 6247.     CrossRef
  • 21,377 View
  • 737 Download
  • 56 Web of Science
  • 53 Crossref
Close layer
Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer
E Sun Paik, Insuk Sohn, Sun-Young Baek, Minhee Shim, Hyun Jin Choi, Tae-Joong Kim, Chel Hun Choi, Jeong-Won Lee, Byoung-Gie Kim, Yoo-Young Lee, Duk-Soo Bae
Cancer Res Treat. 2017;49(3):635-642.   Published online September 27, 2016
DOI: https://doi.org/10.4143/crt.2016.282
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study was conducted to evaluate the prognostic significance of pre-treatment complete blood cell count (CBC), including white blood cell (WBC) differential, in epithelial ovarian cancer (EOC) patients with primary debulking surgery (PDS) and to develop nomograms for platinum sensitivity, progression-free survival (PFS), and overall survival (OS).
Materials and Methods
We retrospectively reviewed the records of 757 patients with EOC whose primary treatment consisted of surgical debulking and chemotherapy at Samsung Medical Center from 2002 to 2012. We subsequently created nomograms for platinum sensitivity, 3-year PFS, and 5-year OS as prediction models for prognostic variables including age, stage, grade, cancer antigen 125 level, residual disease after PDS, and pre-treatment WBC differential counts. The models were then validated by 10-fold cross-validation (CV).
Results
In addition to stage and residual disease after PDS, which are known predictors, lymphocyte and monocyte count were found to be significant prognostic factors for platinum-sensitivity, platelet count for PFS, and neutrophil count for OS on multivariate analysis. The area under the curves of platinum sensitivity, 3-year PFS, and 5-year OS calculated by the 10-fold CV procedure were 0.7405, 0.8159, and 0.815, respectively.
Conclusion
Prognostic factors including pre-treatment CBC were used to develop nomograms for platinum sensitivity, 3-year PFS, and 5-year OS of patients with EOC. These nomograms can be used to better estimate individual outcomes.

Citations

Citations to this article as recorded by  
  • The Gustave Roussy immune score as a novel scoring system for predicting platinum resistance in advanced high-grade serous ovarian cancer
    Xianglin Nie, Ting Xu, Lin Zhang, Wenjun Cheng
    European Journal of Obstetrics & Gynecology and Reproductive Biology.2024; 294: 97.     CrossRef
  • Predictive Value of Machine Learning for Platinum Chemotherapy Responses in Ovarian Cancer: Systematic Review and Meta-Analysis
    Qingyi Wang, Zhuo Chang, Xiaofang Liu, Yunrui Wang, Chuwen Feng, Yunlu Ping, Xiaoling Feng
    Journal of Medical Internet Research.2024; 26: e48527.     CrossRef
  • Candidate prognostic biomarkers and prediction models for high-grade serous ovarian cancer from urinary proteomics
    Maowei Ni, Danying Wan, Junzhou Wu, Wangang Gong, Junjian Wang, Zhiguo Zheng
    Journal of Proteomics.2024; 304: 105234.     CrossRef
  • Preoperative Immune Cell Dysregulation Accompanies Ovarian Cancer Patients into the Postoperative Period
    Jonas Ulevicius, Aldona Jasukaitiene, Arenida Bartkeviciene, Zilvinas Dambrauskas, Antanas Gulbinas, Daiva Urboniene, Saulius Paskauskas
    International Journal of Molecular Sciences.2024; 25(13): 7087.     CrossRef
  • A nomogram with Ki-67 in the prediction of postoperative recurrence and death for glioma
    Fengfeng Li, Dongyuan Wang, Nana Wang, Linlin Wu, Bo Yu
    Scientific Reports.2024;[Epub]     CrossRef
  • Machine learning for epithelial ovarian cancer platinum resistance recurrence identification using routine clinical data
    Li-Rong Yang, Mei Yang, Liu-Lin Chen, Yong-Lin Shen, Yuan He, Zong-Ting Meng, Wan-Qi Wang, Feng Li, Zhi-Jin Liu, Lin-Hui Li, Yu-Feng Wang, Xin-Lei Luo
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Comparison of older and younger patients with ovarian cancer: A post hoc study (JGOG3016‐A3) of the treatment strength and prognostic outcomes of conventional or dose‐dense chemotherapy
    Yoshio Itani, Hitomi Sakai, Tetsutaro Hamano, Mikiko Asai‐Sato, Masayuki Futagami, Masaki Fujimura, Yoichi Aoki, Nao Suzuki, Yoshio Yoshida, Takayuki Enomoto
    Journal of Obstetrics and Gynaecology Research.2023; 49(5): 1400.     CrossRef
  • Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives
    Stanislas Quesada, Michel Fabbro, Jérôme Solassol
    Cancers.2022; 14(4): 1098.     CrossRef
  • Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma
    Suhyun Hwangbo, Se Ik Kim, Ju-Hyun Kim, Kyung Jin Eoh, Chanhee Lee, Young Tae Kim, Dae-Shik Suh, Taesung Park, Yong Sang Song
    Cancers.2021; 13(8): 1875.     CrossRef
  • Beyond BRCA Status: Clinical Biomarkers May Predict Therapeutic Effects of Olaparib in Platinum-Sensitive Ovarian Cancer Recurrence
    Kazuho Nakanishi, Takashi Yamada, Gen Ishikawa, Shunji Suzuki
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study
    Alberto Farolfi, Emanuela Scarpi, Filippo Greco, Alice Bergamini, Lucia Longo, Sandro Pignata, Claudia Casanova, Gennaro Cormio, Alessandra Bologna, Michele Orditura, Laura Zavallone, Laura Attademo, Valentina Gallà, Elisena Franzese, Eva Pigozzi, Vera Lo
    Scientific Reports.2020;[Epub]     CrossRef
  • Pertinence des marqueurs tumoraux, scores (cliniques et biologiques) et algorithmes à visée diagnostique et pronostique devant une masse ovarienne suspecte d’un cancer épithélial. Article rédigé sur la base de la recommandation nationale de bonnes pratiqu
    S. Bendifallah, G. Body, E. Daraï, L. Ouldamer
    Gynécologie Obstétrique Fertilité & Sénologie .2019; 47(2): 134.     CrossRef
  • Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer
    Se Ik Kim, Minsun Song, Suhyun Hwangbo, Sungyoung Lee, Untack Cho, Ju-Hyun Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Dae-Shik Suh, Taesung Park, Yong-Sang Song
    Cancer Research and Treatment.2019; 51(3): 1144.     CrossRef
  • 11,771 View
  • 283 Download
  • 14 Web of Science
  • 13 Crossref
Close layer
Proton Pump Inhibition Enhances the Cytotoxicity of Paclitaxel in Cervical Cancer
Taejong Song, Hye-Kyung Jeon, Ji Eun Hong, Jung-Joo Choi, Tae-Joong Kim, Chel Hun Choi, Duk-Soo Bae, Byoung-Gie Kim, Jeong-Won Lee
Cancer Res Treat. 2017;49(3):595-606.   Published online September 27, 2016
DOI: https://doi.org/10.4143/crt.2016.034
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study was conducted to investigate whether a proton pump inhibitor (PPI) could enhance chemosensitivity via the inhibition of vacuolar-type H+ ATPase (V-ATPase) in cervical cancer.
Materials and Methods
The expression of V-ATPase was evaluated in 351 formalin-fixed, paraffin-embedded human cervical cancer tissues using immunohistochemistry and compared with clinicopathologic risk factors for disease prognosis. The influence of cell proliferation and apoptosis following V-ATPase siRNA transfection or esomeprazole pretreatment was assessed in cervical cancer cell lines using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide and enzyme-linked immunosorbent assay, respectively.
Results
Immunohistochemical analysis revealed that V-ATPase was expressed in about 60% of cervical cancer tissue samples (211/351), and the expression was predominantly found in adenocarcinoma histology (p=0.016). Among patients with initially bulky cervical cancer (n=89), those with V-ATPase expression had shorter disease-free survival (p=0.005) and overall survival (p=0.023). Co-treatment with V-ATPase siRNA or esomeprazole with paclitaxel significantly decreased the cell proliferation of cervical cancer cell lines, including HeLa and INT407, compared to cell lines treated with paclitaxel alone (p < 0.01). Moreover, V-ATPase siRNA or esomeprazole followed by paclitaxel significantly increased the expression of active caspase-3 in these cells compared to cells treated with paclitaxel alone (both, p < 0.05).
Conclusion
V-ATPase was predominantly expressed in cervical adenocarcinoma, and the expression of V-ATPases was associated with poor prognosis. The inhibition of V-ATPase via siRNA or PPI (esomeprazole) might enhance the chemosensitivity of paclitaxel in cervical cancer cells.

Citations

Citations to this article as recorded by  
  • Proton Pump Inhibitor Use and Obesity-Associated Cancer in the Women’s Health Initiative
    Tarah J. Ballinger, Zora Djuric, Sagar Sardesai, Kathleen M. Hovey, Chris A. Andrews, Theodore M. Brasky, Jian Ting Zhang, Thomas E Rohan, Nazmus Saquib, Aladdin H. Shadyab, Michael Simon, Jean Wactawski-Wende, Robert Wallace, Ikuko Kato
    Nutrition and Cancer.2023; 75(1): 265.     CrossRef
  • Esomeprazole Alleviates Cisplatin Resistance by Inhibiting the AKT/mTOR Pathway in Ovarian Cancer Cells
    Jingya Duan, Zisen Zhang, Jinfeng Du, Jihua Zhang, Minmin Li, Canyu Li
    OncoTargets and Therapy.2023; Volume 16: 425.     CrossRef
  • Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota
    Liang Tian, Chongfei Huang, Wenkang Fu, Long Gao, Ningning Mi, Mingzhen Bai, Haidong Ma, Chao Zhang, Yawen Lu, Jinyu Zhao, Xianzhuo Zhang, Ningzu Jiang, Yanyan Lin, Ping Yue, Jinqiu Yuan, Wenbo Meng
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • Depression Events Associated with Proton-Pump Inhibitors in Postmarketing Drug Surveillance Data
    Tigran Makunts, Haroutyun Joulfayan, Kenneth Ta, Ruben Abagyan
    Pharmacoepidemiology.2023; 2(3): 272.     CrossRef
  • Association between Proton Pump Inhibitor Use and the Risk of Female Cancers: A Nested Case-Control Study of 23 Million Individuals
    Nhi Thi Hong Nguyen, Chih-Wei Huang, Ching-Huan Wang, Ming-Chin Lin, Jason C. Hsu, Min-Huei Hsu, Usman Iqbal, Phung-Anh Nguyen, Hsuan-Chia Yang
    Cancers.2022; 14(24): 6083.     CrossRef
  • Emerging insights on the role of V‐ATPase in human diseases: Therapeutic challenges and opportunities
    Cátia Santos‐Pereira, Lígia R. Rodrigues, Manuela Côrte‐Real
    Medicinal Research Reviews.2021; 41(4): 1927.     CrossRef
  • Omeprazole improves chemosensitivity of gastric cancer cells by m6A demethylase FTO-mediated activation of mTORC1 and DDIT3 up-regulation
    Shuitu Feng, Guoqin Qiu, Lihong Yang, Lihua Feng, Xin Fan, Fang Ren, Kaida Huang, Yide Chen
    Bioscience Reports.2021;[Epub]     CrossRef
  • Precise Cancer Anti-acid Therapy Monitoring Using pH-Sensitive MnO2@BSA Nanoparticles by Magnetic Resonance Imaging
    Rong A, Yuzhu Yao, Xiaolu Guo, Weiqi Jiang, Meng Jiang, Jie Yang, Yingbo Li, Olagbaju Oluwatosin Atinuke, Xuesong Hu, Yuanyuan Li, Xiance Wang, Lili Yang, Xiangliang Yang, Kai Wang, Jun Hu, Xilin Sun
    ACS Applied Materials & Interfaces.2021; 13(16): 18604.     CrossRef
  • Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition
    Deepak Babu, Anwita Mudiraj, Neera Yadav, Chandrashekhar Y.B.V.K., Manas Panigrahi, Phanithi Prakash Babu
    Cellular Oncology.2021; 44(4): 889.     CrossRef
  • How can proton pump inhibitors damage central and peripheral nervous systems?
    Tigran Makunts, Ruben Abagyan
    Neural Regeneration Research.2020; 15(11): 2041.     CrossRef
  • Exploring the Therapeutic Potential of Membrane Transport Proteins: Focus on Cancer and Chemoresistance
    Shekoufeh Almasi, Yassine El Hiani
    Cancers.2020; 12(6): 1624.     CrossRef
  • Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells
    Valentina Ranzuglia, Ilaria Lorenzon, Ilenia Pellarin, Maura Sonego, Alessandra Dall’Acqua, Sara D’Andrea, Sara Lovisa, Ilenia Segatto, Michela Coan, Jerry Polesel, Diego Serraino, Patrizia Sabatelli, Paola Spessotto, Barbara Belletti, Gustavo Baldassarre
    Oncogene.2020; 39(40): 6370.     CrossRef
  • Elevated expression of the V‐ATPase D2 subunit triggers increased energy metabolite levels in KrasG12D‐driven cancer cells
    Jigang Yang, Feihu Guo, Leilei Yuan, Guangxin Lv, Jianhua Gong, Jing Chen
    Journal of Cellular Biochemistry.2019; 120(7): 11690.     CrossRef
  • Pantoprazole attenuates tumorigenesis via inhibition of exosomal secretion in a rat model of hepatic precancerous lesion induced by diethylnitrosamine and 2‐acetamidofluorene
    Marwa Matboli, Asmaa Abd ElGwad, Amany H. Hasanin, Ahmed El‐Tawdi, Eman K. Habib, Rasha Ahmed` Elmansy, Doaa Ibrahim, Hanan Shehata, Fathy Tash
    Journal of Cellular Biochemistry.2019; 120(9): 14946.     CrossRef
  • Vacuolar ATPase as a potential therapeutic target and mediator of treatment resistance in cancer
    Bradleigh Whitton, Haruko Okamoto, Graham Packham, Simon J. Crabb
    Cancer Medicine.2018; 7(8): 3800.     CrossRef
  • Protein Pump Inhibitors Esomeprazole and Pantoprazole Increase the Chemosensitivity of CML cells against Imatinib
    Merve Ergül, Mustafa Ergül
    Cumhuriyet Medical Journal.2018;[Epub]     CrossRef
  • Value of pH regulators in the diagnosis, prognosis and treatment of cancer
    Sara Granja, Diana Tavares-Valente, Odília Queirós, Fátima Baltazar
    Seminars in Cancer Biology.2017; 43: 17.     CrossRef
  • Triple-edged therapy targeting intracellular alkalosis and extracellular acidosis in cancer
    Tomas Koltai
    Seminars in Cancer Biology.2017; 43: 139.     CrossRef
  • 11,695 View
  • 402 Download
  • 21 Web of Science
  • 18 Crossref
Close layer
Prognostic Value of Different Patterns of Squamous Cell Carcinoma Antigen Level for the Recurrent Cervical Cancer
Bae Kwon Jeong, Seung Jae Huh, Doo Ho Choi, Won Park, Duk Soo Bae, Byoung-Gie Kim
Cancer Res Treat. 2013;45(1):48-54.   Published online March 31, 2013
DOI: https://doi.org/10.4143/crt.2013.45.1.48
AbstractAbstract PDFPubReaderePub
PURPOSE
In some unusual cases, in patients with cervical cancer, an elevation of squamous cell carcinoma antigen (SCC-Ag) was not observed at diagnosis but was observed on recurrence, or vice versa. The objective of this study was to identify patient-, disease-, and treatment-related factors associated with this unusual level of SCC-Ag, and to determine whether SCC-Ag is a useful tumor marker in such patients.
MATERIALS AND METHODS
Among 129 patients with recurrence, 14 who showed a normal SCC-Ag level at diagnosis but an elevated level at recurrence were classified as group I; 22 patients with an elevated SCC-Ag level at diagnosis but not at recurrence were classified as group II; and 76 patients with an elevated SCC-Ag level at both diagnosis and recurrence were classified as group III.
RESULTS
In univariate analysis, unusual SCC-Ag showed statistically significant relationships with pathology and biochemical response to treatment. However, in the multivariate analysis, none of the clinicopathologic factors showed a statistical relationship with unusual levels of SCC-Ag. The 5-year disease-free survival rates for groups I, II, and III were 7.1%, 9.1%, and 0% (p=0.418), and the 5-year overall survival rates were 34.3%, 58.4%, and 33.3% (p=0.142), respectively.
CONCLUSION
The value of SCC-Ag has been confirmed in all patients; thus, check of SCC-Ag level at follow-up should be considered. Although no statistically significant differences were observed among the groups, we conclude that patients with a high initial SCC-Ag and elevated SCC-Ag at relapse have poor prognosis due to high SCC-Ag level.

Citations

Citations to this article as recorded by  
  • Predictors of distant metastasis or local recurrent after radiotherapy in patients with cervical cancer
    Chufan Wu, Xiaojuan Lv, Fangfang Wang, Qing Xu, Hanmei Lou, Xiaojing Zhang
    BMC Cancer.2025;[Epub]     CrossRef
  • Utility of vaginal vault cytology in the local recurrence of cervical cancer
    Kazuto Nakamura, Soichi Yamashita, Keiko Kigure, Toshio Nishimura, Ikuro Ito, Anri Azuma, Kohshiro Nakao, Ken Ando, Tatsuya Kanuma
    BMC Women's Health.2023;[Epub]     CrossRef
  • Study on the preoperative value of serum SCC-Ag in predicting the stromal invasion of cervical squamous cell carcinoma
    Lin Qin
    Journal of Cancer Research and Clinical Oncology.2023; 149(11): 9167.     CrossRef
  • Prognostic Effect of Primary Recurrence Patterns in Squamous Cervical Carcinoma After Radical Surgery
    Zongkai Zhang, Long Jiang, Rui Bi, Xiaohua Wu, Guihao Ke, Jun Zhu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Can serial evaluation of serum SCC-Ag-level predict tumor recurrence and patient survival in squamous-cell carcinoma of uterine cervix treated with definitive chemoradiotherapy? A multi-institutional analysis
    Kyu Hye Choi, Mina Yu, Songmi Jeong, Jong Hoon Lee
    International Journal of Clinical Oncology.2020; 25(7): 1405.     CrossRef
  • Preoperative SCC-Ag as a predictive marker for the use of adjuvant chemotherapy in cervical squamous cell carcinoma with intermediate-risk factors
    Hong-tao Guo, Xue-han Bi, Ting Lei, Xiao Lv, Guang Yao, Yao Chen, Chang Liu
    BMC Cancer.2020;[Epub]     CrossRef
  • Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: a multi-institutional analysis
    Kyu Hye Choi, Sea-Won Lee, Mina Yu, Songmi Jeong, Jeong Won Lee, Jong Hoon Lee
    Journal of Gynecologic Oncology.2019;[Epub]     CrossRef
  • Prognostic Role of Squamous Cell Carcinoma Antigen in Cervical Cancer: A Meta-analysis
    Zhenhua Liu, Hongtai Shi
    Disease Markers.2019; 2019: 1.     CrossRef
  • The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma: A systematic review and meta-analysis
    Chuenkamon Charakorn, Kunlawat Thadanipon, Sawarat Chaijindaratana, Sasivimol Rattanasiri, Pawin Numthavaj, Ammarin Thakkinstian
    Gynecologic Oncology.2018; 150(1): 190.     CrossRef
  • Squamous cell carcinoma antigen expression in tumor cells is associated with the chemosensitivity and survival of patients with cervical cancer receiving docetaxel-carboplatin-based neoadjuvant chemotherapy
    Peng Chen, Liang Jiao, Dan-Bo Wang
    Oncology Letters.2017; 13(3): 1235.     CrossRef
  • C14ORF166 overexpression is associated with pelvic lymph node metastasis and poor prognosis in uterine cervical cancer
    Weijing Zhang, Jianping Ou, Fangyong Lei, Teng Hou, Shu Wu, Chunhao Niu, Liqun Xu, Yanna Zhang
    Tumor Biology.2016; 37(1): 369.     CrossRef
  • The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease
    Beata Kotowicz, Malgorzata Fuksiewicz, Joanna Jonska-Gmyrek, Mariusz Bidzinski, Maria Kowalska
    Tumor Biology.2016; 37(1): 1271.     CrossRef
  • The Value of Diffusion-Weighted Imaging in Predicting the Prognosis of Stage IB-IIA Cervical Squamous Cell Carcinoma After Radical Hysterectomy
    Guoxing Zhou, Xiao Chen, Fei Tang, Jie Zhou, Yibin Wang, Zhongqiu Wang
    International Journal of Gynecological Cancer.2016; 26(2): 361.     CrossRef
  • Relationship of 18F-Fdg Pet/Ct Metabolic, Clinical and Pathological Characteristics of Primary Squamous Cell Carcinoma of the Cervix
    Weina Xu, Shupeng Yu, Jun Xin, Qiyong Guo
    Journal of Investigative Medicine.2016; 64(8): 1246.     CrossRef
  • Ultrasensitive nonenzymatic immunosensor based on bimetallic gold–silver nanoclusters synthesized by simple mortar grinding route
    Xiaoyue Zhang, Feng Li, Qin Wei, Bin Du, Dan Wu, He Li
    Sensors and Actuators B: Chemical.2014; 194: 64.     CrossRef
  • Detection of cervical cancer recurrence during follow-up: A multivariable comparison of 9 frequently investigated serum biomarkers
    Jacob P. Hoogendam, Afra Zaal, Emma G.G.M. Rutten, Cobi J. Heijnen, Gemma G. Kenter, Wouter B. Veldhuis, René H.M. Verheijen, Ronald P. Zweemer
    Gynecologic Oncology.2013; 131(3): 655.     CrossRef
  • 10,928 View
  • 59 Download
  • 16 Crossref
Close layer
Case Reports
Metastatic Skin Lesions on Lower Extremities in a Patient with Recurrent Serous Papillary Ovarian Carcinoma: A Case Report and Literature Review
Moon-Kyung Kim, Seo-Hee Kim, Yoo-Young Lee, Chel Hun Choi, Tae-Joong Kim, Jeoung-Won Lee, Je-Ho Lee, Duk-Soo Bae, Byoung-Gie Kim
Cancer Res Treat. 2012;44(2):142-145.   Published online June 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.2.142
AbstractAbstract PDFPubReaderePub
Clinical observation of skin metastasis in ovarian cancer cases is relatively uncommon. And distant metastatic skin lesions including the extremities are much rarer still as most metastatic skin lesions are located in the skin in the abdominal wall adjacent to where the primary ovarian tumors exist. We report the case of a 60-year-old woman who presented skin lesions on both lower extremities as a consequence of the metastasis of serous papillary adenocarcinoma of the ovary. She presented with erythematous and painful cutaneous nodules on both upper legs and in the inguinal area 42 months after initial diagnosis of ovarian cancer. Skin biopsy revealed metastasis of adenocarcinoma in the dermis. She was treated with surgical excision and systemic chemotherapy. Literature review has suggested that a combined modality approach including surgical excision and chemotherapy may be useful in the management of skin metastases due to ovarian cancer.

Citations

Citations to this article as recorded by  
  • Cutaneous Metastases—Histological Particularities of Multifaceted Entities
    Andreea Cătălina Tinca, Bianca Andreea Lazar, Andreea Raluca Cozac-Szőke, Georgian Nicolae Radu, Simina Petra Simion, Diana Maria Chiorean, Irina Bianca Kosovski, Adrian Horațiu Sabău, Raluca Niculescu, Iuliu Gabriel Cocuz, Raluca-Diana Hagău, Emoke Andre
    Dermatopathology.2025; 12(2): 14.     CrossRef
  • Skin metastasis from ovarian cancer with somatic BRCA1 mutation: A case report and literature review
    Jingheng Zhang, Wenfeng He, Zhenhua Zhang, Hui Dong, Xiangyu Deng, Qinglian Wen, Dan Li
    Oncology Letters.2024;[Epub]     CrossRef
  • Metastasis of ovarian cancer to nasal skin and skin on the trunk: a rare case report
    Chen Chen, Ouyang Yingyao, Xiang Yan, He Qianru, Wang Hong, Chen Chen, Yang Lei
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • A Rare and Sinister Presentation of Cutaneous Metastasis over Right Lower Limb in a Case of Ovarian Carcinoma
    Preema Sinha, Parul Kamboj, Anamika Sinha, Juhi Sharma
    Journal of Marine Medical Society.2022; 24(2): 211.     CrossRef
  • Clinicopathologic features of cutaneous metastases from internal malignancies
    Hyeong Mok Kwon, Gyu Yeong Kim, Dong Hoon Shin, Young Kyung Bae
    Journal of Pathology and Translational Medicine.2021; 55(4): 289.     CrossRef
  • Rare Sites Metastasis in Ovarian Carcinoma: a Compilation of 3 Case Reports
    Megha Nandwani, Debabrata Barmon, Dimpy Begum, Amal C. Kataki
    Indian Journal of Surgical Oncology.2020; 11(1): 150.     CrossRef
  • Cutaneous metastasis of PD-L1 positive ovarian carcinoma
    Victoria Hastings, Jennifer McEachron, Marguax J. Kanis
    Gynecologic Oncology Reports.2020; 33: 100607.     CrossRef
  • PET/CT for Evaluation of Ovarian Cancer
    Jukka Kemppainen, Johanna Hynninen, Johanna Virtanen, Marko Seppänen
    Seminars in Nuclear Medicine.2019; 49(6): 484.     CrossRef
  • Cutaneous Metastases in Ovarian Cancer
    Isao Otsuka
    Cancers.2019; 11(9): 1292.     CrossRef
  • Skin metastases in ovarian clear cell adenocarcinoma: a case report and a review of the literature
    Gina Nam, Young-mee Lim, Min Sun Cho, Junghye Lee, Yun Hwan Kim
    Obstetrics & Gynecology Science.2017; 60(6): 593.     CrossRef
  • Two independent incidences of skin metastases in the umbilicus and abdominal wall in ovarian serous adenocarcinoma
    Hongyan Cheng, Chunmei Gao, Runtong Zhang, Zhaojie Yang, Guiyu Zhang
    Medicine.2017; 96(49): e9118.     CrossRef
  • Cutaneous metastases from adenocarcinoma of the ovary
    Heidi H. McDonald, Milton R. Moore, Jeffrey J. Meffert
    JAAD Case Reports.2016; 2(5): 406.     CrossRef
  • Ovarian carcinoma presenting as cutaneous nasal metastasis
    Ana Marta António, João Vitor Alves, João Goulão, Elvira Bártolo
    Anais Brasileiros de Dermatologia.2016; 91(5 suppl 1): 101.     CrossRef
  • 12,396 View
  • 72 Download
  • 13 Crossref
Close layer
Benign Metastasizing Leiomyoma with Multiple Lymph Node Metastasis: A Case Report
Gun Yoon, Tae-Joong Kim, Chang-Ohk Sung, Chel Hun Choi, Jeong-Won Lee, Je-Ho Lee, Duk-Soo Bae, Byoung-Gie Kim
Cancer Res Treat. 2011;43(2):131-133.   Published online June 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.2.131
AbstractAbstract PDFPubReaderePub
This is a case report about benign metastasizing leiomyoma with multiple lymph node metastasis. A 34-year-old woman received an abdominal myomectomy for a suspicious leiomyoma. On the pathology report, atypical leiomyoma was suspected. Due to the suspicion of multiple lymph node metastasis on pelvis computed tomography (CT) 1 year after the operation, she was transferred to the Samsung Medical Center on October, 2009 for further work up. According to original slide review, it was determined to be a benign leiomyoma with a mitotic count <5/10 high-power fields, little cytological atypia and no tumor cell necrosis. Additional immunostaining was done. Multiple lymph node metastasis and a small lung nodule were identified on positron emission tomogarphy-CT and chest CT. Extensive debulking surgery and diagnostic video-assisted thoracoscopic surgery (VATS) wedge resection were subsequently done. Metastatic lesions were reported to have a histology similar to that of the original mass. VATS right upper lobectomy with mediastinal lymph node dissection was performed because of the pathology result of VATS (adenocarcinoma). She started taking an aromatase inhibitor (Letrozole(R)) and there was no evidence of recurrence of disease on an imaging study and no post-operative complications until recently.

Citations

Citations to this article as recorded by  
  • Pulmonary Benign Metastasizing Leiomyoma in a Postmenopausal Woman: A Case Report and Review of the Literature
    Aleksandra Piórek, Adam Płużański, Piotr Wiśniewski, Sylwia Tabor, Kinga Winiarczyk, Magdalena Knetki-Wróblewska, Dariusz M. Kowalski, Maciej Krzakowski
    Diseases.2024; 12(8): 181.     CrossRef
  • Leiomiomatosis pulmonar benigna metastatizante: una causa rara de nódulos pulmonares. Reporte de caso
    María Angélica Moreno Carrillo, María Carolina Torres, Alfredo Saavedra, Rafael Parra Medina
    Revista Colombiana de Neumología.2024; 36(1): 48.     CrossRef
  • Benign metastasizing uterine leiomyoma with lymphatic and pulmonary metastases: a case report and literature review
    Tong Tong, Qiong Fan, Yudong Wang, Yuhong Li
    BMC Women's Health.2023;[Epub]     CrossRef
  • Pulmonary benign metastasizing uterine leiomyoma (PBML): a case report and review of the literature
    Mark R. Brincat, Sarah Lam Shang Leen, Asma Faruqi, Michail Sideris, Kelvin Kar Wing Lau, Alexandra Lawrence
    Annals of Medicine & Surgery.2023; 85(7): 3686.     CrossRef
  • Benign Metastasizing Leiomyoma of the Lung: Diagnostic Process and Treatment Based on Three Case Reports and a Review of the Literature
    Małgorzata Edyta Wojtyś, Olga Kacalska-Janssen, Konrad Ptaszyński, Piotr Lisowski, Michał Kunc, Janusz Wójcik, Tomasz Grodzki
    Biomedicines.2022; 10(10): 2465.     CrossRef
  • A case report of atypical uterine leiomyoma
    Yun Sook Kim, Hyun Joo Lee
    Medicine: Case Reports and Study Protocols.2021; 3(11): e0168.     CrossRef
  • Metastatic leiomyoma or synchronous lesion of the uteri corpus and vulva?
    I. V. Barinova, S. N. Buyanova, N. I. Kondrikov, N. A. Shchukina, I. N. Voloshchuk, M. V. Mgeliashvili, S. A. Petrakova, A. A. Aksenova
    Arkhiv patologii.2020; 82(1): 62.     CrossRef
  • Lung metastases from benign uterine leiomyoma: does 18-FDG-PET/CT have a role to play?
    Feras Abu Saadeh, Ciaran O. Riain, Ciara Mc Cormack, Noreen Gleeson
    Irish Journal of Medical Science (1971 -).2019; 188(2): 619.     CrossRef
  • Benign metastasising leiomyoma with lymph node metastases in a patient with endometrial cancer after caesarean section
    Serra Akar, Serdar Ugras, Gozde Sahin, Fatih Demir, Çetin Çelik
    Journal of Obstetrics and Gynaecology.2019; 39(3): 420.     CrossRef
  • Benign metastasizing leiomyoma presenting with miliary pattern and fatal outcome: Case report with molecular analysis & review of the literature
    Kenneth Ofori, Helen Fernandes, Matthew Cummings, Thomas Colby, Anjali Saqi
    Respiratory Medicine Case Reports.2019; 27: 100831.     CrossRef
  • Gonadotropin-releasing Hormone Agonist Plus Aromatase Inhibitor in the Treatment of Uterine Leiomyoma in Near Menopause Patient: A Case Series Study
    Sanam Moradan
    Journal of Menopausal Medicine.2018; 24(1): 62.     CrossRef
  • The Heart as a Site of Metastasis of Benign Metastasizing Leiomyoma: Case Report and Review of the Literature
    Mariam Meddeb, Robert D. Chow, Randolph Whipps, Reyaz Haque
    Case Reports in Cardiology.2018; 2018: 1.     CrossRef
  • BENIGN UTERUS CANCER WITH LUNG METASTASES: LEIOMYOMATOSIS, LYMPHANGIOLEIMYOMATOSIS, THORACIC ENDOMETRIOSIS (LITERATURE REVIEW, PERSONAL CLINCIAL OBSERVATIONS)
    Леншин, Anatoliy Lenshin, Ильин, Andrey Il'in, Демура, Ol'ga Demura, Крайнов, Sergey Kraynov, Побережский, Aleksey Poberezhskiy
    Bulletin physiology and pathology of respiration .2017; : 30.     CrossRef
  • Benign metastasizing leiomyoma and 18-FDG-PET/CT: A case report and literature review
    Yusuke Sawai, Toshiki Shimizu, Yuta Yamanaka, Maiko Niki, Shosaku Nomura
    Oncology Letters.2017; 14(3): 3641.     CrossRef
  • Mesothelial cell deposits in lymph nodes—a diagnostic pitfall
    Archana Pandita, Vladimir Osipov
    Annals of Diagnostic Pathology.2016; 25: 31.     CrossRef
  • Recommendations and Technical Aspects of 16α-[18F]Fluoro-17β-Estradiol PET to Image the Estrogen Receptor In Vivo
    Clasina M. Venema, Giulia Apollonio, Geke A.P. Hospers, Carolina P. Schröder, Rudi A.J.O. Dierckx, Erik F.J. de Vries, Andor W.J.M. Glaudemans
    Clinical Nuclear Medicine.2016; 41(11): 844.     CrossRef
  • Single benign metastasising leiomyoma of an inguinal lymph node
    Kamil G Laban, Roberto E Tobon-Morales, Janice A L Hodge, Henk W R Schreuder
    BMJ Case Reports.2016; : bcr2016216546.     CrossRef
  • Leiomyomas beyond the uterus; benign metastasizing leiomyomatosis with paraaortic metastasizing endometriosis and intravenous leiomyomatosis: a case series and review of the literature
    Mohamad S. Mahmoud, Kavita Desai, Farr R. Nezhat
    Archives of Gynecology and Obstetrics.2015; 291(1): 223.     CrossRef
  • Benign pulmonary metastasizing leiomyoma of the uterus: A case report
    HUI MA, JIE CAO
    Oncology Letters.2015; 9(3): 1347.     CrossRef
  • Single-port laparoscopic debulking surgery of variant benign metastatic leiomyomatosis with simultaneous lymphatic spreading and intraperitoneal seeding
    Yoo Hyun Chung, Suk Woo Lee, So Young Shin, Chae Chun Rhim, Soyoung Im, Sie Hyeon Yoo, Joo Hee Yoon
    Obstetrics & Gynecology Science.2015; 58(4): 314.     CrossRef
  • Benign metastasizing leiomyoma of the lung: A case report and literature review
    WEI-TIAN WEI, PENG-CHENG CHEN
    Oncology Letters.2015; 10(1): 307.     CrossRef
  • Difficulty in complete transarterial embolization for pulmonary benign metastasizing leiomyoma with massive hemoptysis
    Masaya Miyazaki, Akie Nakayama, Daichi Noda, Yasunobu Maehara, Yoshito Tsushima
    Japanese Journal of Radiology.2014; 32(1): 53.     CrossRef
  • Pulmonary leiomyomas in a patient with bilateral renal cell cancer mimicking pulmonary metastases
    Ying-Yi Chen, Seng-Tang Wu, Hsian-Her Hsu, Ya-Cheng Chen, Shih-Chun Lee, Hung Chang, Tsai-Wang Huang
    Clinical Imaging.2014; 38(3): 330.     CrossRef
  • Incidental Benign Metastasizing Leiomyoma in a Patient with Bone Sarcoma: A Case Report
    Zanndor Jacob del Real-Romo, Carlos Montero-Cantú, Oscar Villegas-Cabello, José Antonio Díaz-Elizondo, Danae Reyes-Salas, Rene Palomo-Hoil, Guillermo Peralta-Castillo, David Martínez-Sánchez, Eduardo Flores-Villalba
    Case Reports in Surgery.2014; 2014: 1.     CrossRef
  • Metastasizing Leiomyoma to Heart
    Erin N. Consamus, Michael J. Reardon, Alberto G. Ayala, Mary R. Schwartz, Jae Y. Ro
    Methodist DeBakey Cardiovascular Journal.2014; 10(4): 251.     CrossRef
  • METASTASISING LEIOMYOMA- A CASE REPORT
    Krishna Govindan, Sheela Kuzhiveli Mohammed Ali, Lekshmy Kausthubham Sudheendran
    Journal of Evolution of Medical and Dental Sciences.2014; 7(42): 4591.     CrossRef
  • Benign Metastatic Leiomyoma Presenting as a Hemothorax
    Anna M. Ponea, Creticus P. Marak, Harmeen Goraya, Achuta K. Guddati
    Case Reports in Oncological Medicine.2013; 2013: 1.     CrossRef
  • Novel hormone treatment of benign metastasizing leiomyoma: an analysis of five cases and literature review
    Erin I. Lewis, Rebecca J. Chason, Alan H. DeCherney, Alicia Armstrong, John Elkas, Aradhana M. Venkatesan
    Fertility and Sterility.2013; 99(7): 2017.     CrossRef
  • Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models
    Bosung Shim, Gustavo Pacheco-Rodriguez, Jiro Kato, Thomas N. Darling, Martha Vaughan, Joel Moss
    European Respiratory Review.2013; 22(129): 302.     CrossRef
  • Pulmonary benign metastasizing leiomyoma: a case report and review of the literature
    Yili Fu, Hui Li, Bo Tian, Bin Hu
    World Journal of Surgical Oncology.2012;[Epub]     CrossRef
  • 12,478 View
  • 71 Download
  • 30 Crossref
Close layer
Original Articles
Uterine Leiomyosarcoma : 14-year Two-center Experience of 31 Cases
Woo Young Kim, Suk-Joon Chang, Ki-Hong Chang, Jong-Hyuck Yoon, Jang Hee Kim, Byoung-Gie Kim, Duk-Soo Bae, Hee-Sug Ryu
Cancer Res Treat. 2009;41(1):24-28.   Published online March 31, 2009
DOI: https://doi.org/10.4143/crt.2009.41.1.24
AbstractAbstract PDFPubReaderePub
Purpose

The aim of this study was to evaluate the clinicopathological characteristics of uterine leiomyosarcoma (LMS) and possible prognostic factors.

Materials and Methods

This study included 31 patients with histologically proven LMS at Samsung Medical Center and Ajou University Hospital between 1994 and 2007. The medical records and available histological slides were reviewed retrospectively.

Results

The median age was 46 years (range, 32~63). The most common symptom was vaginal bleeding (11 patients, 35.5%). There were 23 patients with stage I, one patient with stage III, seven patients with stage IV disease. The median follow up time was 29 months (range, 1~94). The most common recurrence site was lung (5 case), followed by pelvis and upper abdomen (2 case). Nine patients died of disease with a 5-year overall survival rate of 63%. Early tumor stage and mitotic count were the prognostic factor in univariate analysis (p<0.0001 and p=0.0031, respectively), but early tumor stage only was associated with prognosis in multivariate analysis (p=0.010 vs p=0.143). Adjuvant treatment for early stage disease did not decrease the recurrence rate (p=0.1075), but high mitotic count (15>10HPF) had a trend for disease recurrence in early stage LMS (p=0.0859).

Conclusion

Mitotic count less than 15/HPF in early stage may be related with longer progression-free interval, but we could not reach the conclusion that adjuvant therapy in early stage LMS be effective.

Citations

Citations to this article as recorded by  
  • 2‑D08 mediates notable anticancer effects through multiple cellular pathways in uterine leiomyosarcoma cells
    Hosouk Joung, Hyunju Liu
    Oncology Reports.2024;[Epub]     CrossRef
  • Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma
    Joseph J. Noh, Young-Jae Cho, Ji-Yoon Ryu, Jung-Joo Choi, Jae Ryoung Hwang, Ju-Yeon Choi, Jeong-Won Lee
    Clinical Cancer Research.2022; 28(17): 3850.     CrossRef
  • Epigenetic Features in Uterine Leiomyosarcoma and Endometrial Stromal Sarcomas: An Overview of the Literature
    Bruna Cristine de Almeida, Laura Gonzalez dos Anjos, Andrey Senos Dobroff, Edmund Chada Baracat, Qiwei Yang, Ayman Al-Hendy, Katia Candido Carvalho
    Biomedicines.2022; 10(10): 2567.     CrossRef
  • Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis
    Alessandro Rizzo, Margherita Nannini, Annalisa Astolfi, Valentina Indio, Pierandrea De Iaco, Anna Myriam Perrone, Antonio De Leo, Lorena Incorvaia, Valerio Di Scioscio, Maria Abbondanza Pantaleo
    Cancers.2020; 12(7): 1899.     CrossRef
  • Adjuvant Chemotherapy in Uterine Leiomyosarcoma: Trends and Factors Impacting Usage
    Dhara Patel, Elizabeth Handorf, Margaret von Mehren, Lainie Martin, Sujana Movva
    Sarcoma.2019; 2019: 1.     CrossRef
  • Prognostic factors for recurrence and survival in uterine leiomyosarcoma: Korean single center experience with 50 cases
    E Sun Paik, Jae Hong Kang, Jihye Kim, Yeon-Joo Lee, Chel Hun Choi, Tae-Joong Kim, Byoung-Gie Kim, Duk-Soo Bae, Jeong-Won Lee
    Obstetrics & Gynecology Science.2019; 62(2): 103.     CrossRef
  • Effect of adjuvant therapy on the risk of recurrence in early-stage leiomyosarcoma: A meta-analysis
    Su Hyun Chae, Seung-Hyuk Shim, Misoo Chang, Ah Young Choi, Gun Gu Kang, Sun Joo Lee, Soo-Nyung Kim
    Gynecologic Oncology.2019; 154(3): 638.     CrossRef
  • Clinicopathological Correlation of Uterine Corpus Tumors: A Study of 433 Cases
    Divya Shekhar Shetty, Alka Vikas Gosavi, Prashant Shankarrao Murarkar, Kalpana Ranjitsingh Sulhyan
    Indian Journal of Gynecologic Oncology.2019;[Epub]     CrossRef
  • Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: A systematic review and meta-analysis
    Giorgio Bogani, Giovanni Fucà, Giuseppa Maltese, Antonino Ditto, Fabio Martinelli, Mauro Signorelli, Valentina Chiappa, Cono Scaffa, Ilaria sabatucci, Francesca Lecce, Francesco Raspagliesi, Domenica Lorusso
    Gynecologic Oncology.2016; 143(2): 443.     CrossRef
  • Uterine sarcomas and parasitic myomas after laparoscopic hysterectomy with power morcellation
    Jasmine Tan-Kim, Katherine A. Hartzell, Caryl S. Reinsch, Cristina H. O’Day, John S. Kennedy, Shawn A. Menefee, Terry A. Harrison
    American Journal of Obstetrics and Gynecology.2015; 212(5): 594.e1.     CrossRef
  • Successful removal of uterine leiomyosarcoma tumour thrombus propagating to the right atrium
    Yu Hui Lim, Lui Shiong Lee, Chong Hee Lim, Ghee Kheng Chew
    BMJ Case Reports.2015; 2015: bcr2015213384.     CrossRef
  • Lung Metastasis after an Eighteen-Years-Long Disease-Free Period since Uterine Leiomyosarcoma Diagnosis
    M. Guazzaroni, D. Tosti, M. Rascioni, M. Mataloni, D. Citraro, G. Simonetti
    Case Reports in Oncological Medicine.2014; 2014: 1.     CrossRef
  • FIGO Staging for Uterine Sarcomas: Can the Revised 2008 Staging System Predict Survival Outcome Better?
    Ga Won Yim, Eun Ji Nam, Sang Wun Kim, Young Tae Kim
    Yonsei Medical Journal.2014; 55(3): 563.     CrossRef
  • Postoperative radiotherapy improves local control and survival in patients with uterine leiomyosarcoma
    Philip Wong, Kathy Han, Jenna Sykes, Charles Catton, Stephane Laframboise, Anthony Fyles, Lee Manchul, Wilfred Levin, Michael Milosevic
    Radiation Oncology.2013;[Epub]     CrossRef
  • Uterine Sarcomas: Then and Now
    Shaan H. Shah, Jyothi P. Jagannathan, Katherine Krajewski, Kevin N. O???Regan, Suzanne George, Nikhil H. Ramaiya
    American Journal of Roentgenology.2012; 199(1): 213.     CrossRef
  • Prognostic Factors and Outcomes in 28 Cases of Uterine Leiomyosarcoma
    V. Loizzi, G. Cormio, D. Nestola, M. Falagario, A. Surgo, A. Camporeale, G. Putignano, L. Selvaggi
    Oncology.2011; 81(2): 91.     CrossRef
  • Surgical treatment of uterine sarcoma
    Joo-Hyun Nam
    Best Practice & Research Clinical Obstetrics & Gynaecology.2011; 25(6): 751.     CrossRef
  • The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma
    Jeong-Yeol Park, Sun-Kyung Park, Dae-Yeon Kim, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam
    Gynecologic Oncology.2011; 122(2): 255.     CrossRef
  • Co-existence of three rare gynecological tumors in a 79-year-old woman
    Hongkai Zhang, Melinda Lerwill
    Archives of Gynecology and Obstetrics.2011; 284(3): 695.     CrossRef
  • 10,762 View
  • 61 Download
  • 19 Crossref
Close layer
MR Imaging in Endometrial Carcinoma as a Diagnostic Tool for the Prediction of Myometrial Invasion and Lymph Node Metastasis
Ui Nam Ryoo, Chel Hun Choi, Ji Yeong Yoon, Soo Kyung Noh, Heeseok Kang, Woo Young Kim, Boh Hyun Kim, Tae-Joong Kim, Jeong-Won Lee, Je-Ho Lee, Byoung-Gie Kim, Duk-Soo Bae
Cancer Res Treat. 2007;39(4):165-170.   Published online December 31, 2007
DOI: https://doi.org/10.4143/crt.2007.39.4.165
AbstractAbstract PDFPubReaderePub
Purpose

The purpose of this study was to evaluate the factors that are associated with the accuracy of magnetic resonance (MR) imaging for predicting myometrial invasion and lymph node metastasis in women with endometrial carcinoma.

Materials and Methods

We retrospectively reviewed the medical records and preoperative MR imaging reports of 128 women who had pathologically proven endometrial carcinoma. We compared the MR imaging and the histopathology findings.

Results

The sensitivity, specificity and accuracy for identifing any myometrial invasion (superficial or deep) were 0.81, 0.61 and 0.74, respectively; these values for deep myometrial invasion were 0.60, 0.94 and 0.86, respectively. The sensitivity, specificity and accuracy of MR imaging for detecting lymph node metastasis were 50.0%, 96.6% and 93.0%, respectively. The patients who were older, had more deliveries and a larger tumor size more frequently had incorrect prediction of deep myometrial invasion (p=0.034, p=0.044, p=0.061, respectively). A higher tumor grade, a histology other than the endometrioid type, myometrial invasion on MR findings and a larger tumor size were associated with a more frequent false-negative prediction of lymph node metastasis (p=0.018, p=0.017, p=0.002, p=0.047, respectively). A larger tumor size was also associated with more frequent false-positive results (p=0.009).

Conclusions

There are several factors that make accurate assessment of myometrial invasion or lymph node metastasis difficult with using MRI; therefore, the patients with these factors should have their MR findings cautiously interpreted.

Citations

Citations to this article as recorded by  
  • Magnetic resonance imaging pitfalls in determining myometrial invasion in stage I endometrial cancer: A case report and literature review
    Hariyono Winarto, Muhammad Habiburrahman, Trifonia Pingkan Siregar, Kartiwa Hadi Nuryanto
    Radiology Case Reports.2022; 17(8): 2680.     CrossRef
  • Diagnostic Accuracy of Clinical Biomarkers for Preoperative Prediction of Lymph Node Metastasis in Endometrial Carcinoma: A Systematic Review and Meta-Analysis
    Casper Reijnen, Joanna IntHout, Leon F.A.G. Massuger, Fleur Strobbe, Heidi V.N. Küsters-Vandevelde, Ingfrid S. Haldorsen, Marc P.L.M. Snijders, Johanna M.A. Pijnenborg
    The Oncologist.2019; 24(9): e880.     CrossRef
  • Feasibility of a reduced field‐of‐view diffusion‐weighted (rFOV) sequence in assessment of myometrial invasion in patients with clinical FIGO stage I endometrial cancer
    Priya Bhosale, Jingfei Ma, Revathy Iyer, Preetha Ramalingam, Wei Wei, Pamela Soliman, Michael Frumovitz, Vikas Kundra
    Journal of Magnetic Resonance Imaging.2016; 43(2): 316.     CrossRef
  • Contrast‐enhanced MRI in preoperative assessment of myometrial and cervical invasion, and lymph node metastasis: diagnostic value and error analysis in endometrial carcinoma
    Fei Teng, Yan‐Fang Zhang, Ying‐Mei Wang, Jing Yu, Xu Lang, Wen‐Yan Tian, Chang‐Xin Jiang, Feng‐Xia Xue
    Acta Obstetricia et Gynecologica Scandinavica.2015; 94(3): 266.     CrossRef
  • Magnetic Resonance Imaging in the Assessment of High-Risk Features of Endometrial Carcinoma A Meta-Analysis
    Anna Luomaranta, Arto Leminen, Mikko Loukovaara
    International Journal of Gynecological Cancer.2015; 25(5): 837.     CrossRef
  • Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma
    Sami K. Saarelainen, Nina Peltonen, Terho Lehtimäki, Antti Perheentupa, Maarit H. Vuento, Johanna U. Mäenpää
    American Journal of Obstetrics and Gynecology.2013; 209(2): 142.e1.     CrossRef
  • Preoperative assessment of endometrial carcinoma by three‐dimensional power Doppler angiography
    S. K. Saarelainen, M. H. Vuento, P. Kirkinen, J. U. Mäenpää
    Ultrasound in Obstetrics & Gynecology.2012; 39(4): 466.     CrossRef
  • Pre-operative systemic inflammatory response markers in predicting lymph node metastasis in endometrioid endometrial adenocarcinoma
    Dong Hoon Suh, Hee Seung Kim, Hyun Hoon Chung, Jae Weon Kim, Noh Hyun Park, Yong Sang Song, Soon-Beom Kang
    European Journal of Obstetrics & Gynecology and Reproductive Biology.2012; 162(2): 206.     CrossRef
  • The preoperative assessment of deep myometrial invasion by three‐dimensional ultrasound versus MRI in endometrial carcinoma
    SAMI K. SAARELAINEN, LEA KÖÖBI, RITVA JÄRVENPÄÄ, MARITA LAURILA, JOHANNA U. MÄENPÄÄ
    Acta Obstetricia et Gynecologica Scandinavica.2012; 91(8): 983.     CrossRef
  • 10,105 View
  • 91 Download
  • 9 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP